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Abstract
Background: Clostridium difficile is a leading cause of noscomial infection and is
responsible for increased morbidity and mortality (Hookman & Barkin, 2009). There
are limited data available on the nutritional status and dietetic management of these
patients.
Aims:
1. To carry out an observational study to assess the prevalence of the risk of
malnutrition in patients with Clostridium difficile associated disease (CDAD) and
compare it to a group of patients in the same hospital.
2. To investigate dietitians’ beliefs and recommendations of probiotics in CDAD and
determine the probiotic products and strains being used in this patient group. To
assess the current enteral feeding practices of dietitians in patients with CDAD.
Methods: The Malnutrition Screening Tool (MUST) was used to assess the
prevalence of risk of malnutrition in the patients with CDAD and a hospital
comparison group. A questionnaire was sent to members of the Irish Nutrition and
Dietetic Institute to gather information on dietitians’ opinions and use of probiotics
and their enteral feeding practices in patients with CDAD.
Results: There was no significant difference in the prevalence of malnutrition risk
(MUST of 1 or more) between the CDAD group (75.5%) compared to the hospital
comparison group (66.7%). The questionnaire response rate was 41% with 215
questionnaires undergoing analysis. One-third (34.5%) of dietitians considered
probiotics to have a role in the prevention of CDAD yet only 11% used them in
ii

practice. Almost two-thirds (65.4%) believed that they have a role in the treatment of
CDAD but only 40% regularly used them in practice. A yogurt drink containing
Lactobacillus rhamnosus GG was mostly commonly available probiotic product for
use by dietitians. When enterally feeding patients with CDAD, the majority of
dietitians use a polymeric feed (79.6%).

Conclusion: Both patient groups studied were at similar nutritional risk. There are
mixed beliefs among Irish dietitians on the role of probiotics in CDAD. Probiotics
are frequently recommended by dietitians in their clinical practice with little
standardisation in practice. The probiotic strain that is most commonly being used in
patients with CDAD does not have strong evidence to support its use.
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Part 1 - Clostridium difficile associated disease
1.1

Clostridium difficile

The human gastrointestinal tract (GIT) contains up to 1014 microorganisms comprised
of around one thousand different bacterial species (Backhed et al., 2005). Some of
these microorganisms live permanently in the GIT while others are introduced with
food or other contaminants and pass through the tract. The stomach contains very
few resident bacteria due to its low pH. The upper intestine also contains small
numbers of microorganisms due to the presence of bile salts and the action of
peristalsis. A dramatic increase in the number and variety of microorganisms, in
particular, anaerobes is found in the colon. One such anaerobe, estimated to form
part of the faecal flora in approximately 3% of healthy adults, is the gram positive,
spore-forming Clostridium difficile (C.difficile) (Viscidi et al., 1981). The bacterium
was first described in 1935 by Hall and O’Toole as part of the normal intestinal flora
of newborn infants (Hall & O'Toole, 1935). The bacterium is present in over 20% of
hospitalised patients (Starr, 2005) and has been identified in 4-20% of patients in long
term care facilities (Simor et al., 2002). It is a major cause of nosocomial infection,
and has been associated with an increased incidence of morbidity and mortality, in
hospitals and long term care facilities (Loo et al., 2005; McDonald et al., 2005; Pepin
et al., 2005a). In 1978, C. difficile was identified as the pathogen responsible for
pseudomembranous colitis (PMC) (Bartlett et al., 1978).
Acquisition of C. difficile occurs by oral ingestion of spores. These spores are
resistant to the acidity of the stomach and germinate into the vegetative form in the
alkaline environment of the small intestine. Disruption of the commensal flora of the
colon, typically through exposure to antimicrobial medication, allows C. difficile to
flourish and produce toxins. The two main exotoxins that are produced are toxin A
6

and toxin B, both of which are cytotoxic and enteropathic in the human intestine.
Both toxins appear to have cytotoxic effects through disruption of the actin
cytoskeleton within cells (Rupnik et al., 2005). The toxins loosen the junctions of
the epithelial cells that line the colon allowing for penetration between epithelial
cells (Starr, 2005). This begins the cascade of a tissue damaging inflammatory
process that involves releasing destructive leukotrienes and cytokines, with the
subsequent death of epithelial cells by apoptosis. The cytokines identified as being
involved are interleukins (IL) 6, IL8, IL 1β, leukotriene B4 and interferon γ.
Epithelial cells and monocytes have been found to be more sensitive to C. difficle
toxin A induced death than lymphocytes (Mahida et al., 1996). More recently, a
third toxin (binary toxin) encoded by the cdtA and cdtB genes has been found in 10%
of strains (Goncalves et al., 2004). The role of this third toxin in disease development
is still unclear (Pituch, 2009). It has been suggested that it has a clinically relevant
role (Barbut et al., 2005). A correlation between the amount of toxin produced and
the extent of clinical disease is not thought to exist (Akerlund et al., 2006).

1.2

Definition of Clostridium difficile associated disease (CDAD)

The Health Protection Surveillance Centre (HPSC) of Ireland has adopted the
definition of CDAD recommended by the European Society of Clinical Microbiology
and Infectious Diseases (ESCMID) study group for C. difficile and the European
Centre for Disease Prevention and Control (ECDC) (Kuijper et al., 2006). In Ireland,
Clostridium difficile associated disease (CDAD) is diagnosed when patients have one
or more of the following criteria: diarrhoeal stools or toxic megacolon with either a
positive laboratory assay of C. difficile toxin A and/or toxin B in stools or a toxin
producing C. difficile organism detected in stool culture or by other laboratory
methods. PMC can only be diagnosed by endoscopy and/or colonic histopathology.
7

In all cases, diarrhoea is defined as three or more loose or watery bowel movements
in a 24-hour period. Similar criteria are used to diagnose recurrent CDAD (Cohen et
al., 2010).

The infection is classified as severe when there is admission to an

intensive care unit (ICU) for treatment of CDAD or its complications, surgery for
toxic megacolon, perforation or refractory colitis or death within 30 days of diagnosis
if CDAD is either the primary or a contributory cause. Admission to a healthcare
facility for treatment of community associated CDAD is also classified as severe
infection. According to the HPSC, CDAD can also be classified according to its
origin as follows: “Health care associated” CDAD or “Community associated”
CDAD. The HPSC classifies acquisition as “unknown” when CDAD presents in a
patient who was discharged from a healthcare facility 4-12 weeks before the onset of
symptoms (HPSC, 2008).
CDAD has been classified as recurrent if an episode of CDAD occurs within eight
weeks following the onset of a previous episode, provided that the CDAD symptoms
from the earlier episode resolved with or without therapy. Older age, low quality of
life score and being female are known risk factors for disease recurrence (McFarland
et al., 1999). Following a first episode of CDAD, 24% of patients relapse within two
months (Sunenshine & McDonald, 2006).

Having one recurrence of CDAD

increases the risk of subsequent recurrences (McFarland et al., 1999). Re-infection
with different strains of C. difficile has been found in a large proportion of
recurrences (Barbut et al., 2000). The risk of recurring infection increases to 50-65%
of patients with two or more previous episodes (Rohde et al., 2009).
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1.3

Clinical manifestations of CDAD

The spectrum of C. difficile human disease ranges from asymptomatic colonisation to
potentially fatal colitis. Fulminant, life threatening PMC is the extreme end of the
spectrum of disease and occurs in 3-5% of those affected (Jobe et al., 1995; Rubin et
al., 1995). The symptoms of CDAD usually begin soon after colonisation, with
median time to onset of 2-3 days (McFarland et al., 1989; Johnson et al., 1990;
Samore et al., 1994; Kyne et al., 2000). Typically, CDAD presents as diarrhoea,
abdominal cramps, fever and leukocytosis occurring from several days to 10 weeks
after antibiotic therapy (Kelly et al., 1994; Kyne et al., 1999; Bartlett et al., 2002).
Histologically, the disease is characterized by focal epithelial ulceration associated
with inflammatory exudates (Price & Davies, 1977). Severely ill patients may have
no diarrhoea due to dilation of the colon (toxic megacolon) and paralytic ileus that
may result from loss of colonic muscular tone (Kelly et al., 1994; Kyne et al., 1999;
Bartlett et al., 2002). In severely ill patients, with no response to treatment, a
colectomy may be required (Bartlett, 2002). In general, complications of diarrhoea
threaten the already compromised health and well being of the hospitalised patient.
Severe diarrhoea can result in haemodynamic and metabolic instability due to fluid
and electrolyte imbalance.

Incontinence of diarrhoeal stool is a major cause of

perianal skin damage. An unusual manifestation of CDAD was described by
Dansinger et al., (1996) who reported that up to half of patients with indolent C.
difficile infection develop manifestations of protein losing enteropathy involving
ascites, peripheral oedema and hypoalbuminaemia. Inflammation of the bowel may
result in leakage of albumin across the lumen causing colonic loss of albumin with
inadequate

compensatory

hepatic

synthesis

(Hookman

&

Barkin,

2009).

Psychological problems are often overlooked, as diarrhoea can be exhausting and
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embarrassing for the patient (Thorson et al., 2008). Complications result in extended
hospital stay (on average by 3-7 days), an increase in unrelated infections and a two
to three times increased risk of mortality (McFarland, 2006). Kuijper et al., (2006)
have estimated the cost of CDAD to the healthcare system as between €5-15,000 per
case in the United Kingdom. CDAD results in a total expenditure of $1.1 billion per
year in the United States (Kuijper et al., 2006).

1.4

Immune response to CDAD

The host immune response to C. difficile colonisation and toxin production is crucial
in influencing disease severity, but not all patients have a similar immunological
response (Jiang et al., 2007). The earliest research in this area reported an antibody
response in 64% of adults to toxin A and in 66% of adults to toxin B. Antibody
levels to toxin B were higher in the serum of convalescent CDAD patients when
compared to those of a control population (Viscidi et al., 1983). Kyne et al., (2000)
reported that asymptomatic carriage of C. difficile was strongly associated with an
immune response to C. difficile toxins, and this was demonstrated by high serum
levels of IgG antibody against toxin A.

1.5

Changing epidemiology of CDAD

In recent years, there has been an unexpected increase in CDAD infection with large
outbreaks in North America and Europe (Kuijper et al., 2006). In many of the
locations where the increase has been identified, the disease has become more serious
and refractory to standard therapy. These recent outbreaks have been associated with
the unique strain of C. difficile that has been identified as B1/NAP1/027 or “ribotype
027”. This strain is now affecting relatively healthy adults, including some who have
not been exposed to the hospital setting or recent antibiotics. B1/NAP1/027 strain is
characterized as toxinotype III and has a 18-bp deletion within the tcdC gene
10

(putative negative regulator for the production of toxins A and B) as well as a
deletion at position 117. It produces 23 and 16 times more toxin B and A respectively
in vitro than previously described (Warny et al., 2005). This strain has a high
resistance to fluoroquinolones (Pepin et al., 2005a) and the mortality associated with
the new strain has been estimated to be between 6-12% (Pepin et al., 2005b; Smith,
2005; Paltansing et al., 2007).
An increased incidence of the disease has also been identified in the community
setting; again affecting people who would traditionally have been at low risk (Wilcox
et al., 2008). Mc Farland et al., (2007), observed patients with community-acquired
CDAD were younger, had less severe disease and that most had no prior exposure to
antibiotics. It has been suggested that this may be because CDAD is an emerging
problem, or that possibly that the disease was overlooked in the past (Weese, 2010).
A variety of hypotheses has been proposed to explain the current outbreaks of CDAD
in the community. Levels of exposure to the organism and its spores may have
increased due to the possible colonisation of recently discharged patients from
hospitals, increased asymptomatic carriage and increased contact with asymptomatic
carriers (Bauer et al., 2008a). Weese (2010) commented that animals and
contaminated food may be a source of C. difficile, especially in communityassociated CDAD.

1.6

CDAD in Ireland

Until recently there was limited information from the Republic of Ireland on CDAD.
However, in May 2008, it became a notifiable disease. In 2009, there were 1897 new
cases of CDAD reported (HPSC, 2009) and this decreased to 1696 new cases in 2010
(HPSC, 2010). In both years, the disease was more prevalent in females (59% in
11

2010) and in those over 65 years of age (HPSC, 2009; HPSC, 2010).

Further

information about the disease in Ireland was captured during a one month national
enhanced surveillance in March 2009. Typing and antimicrobial susceptibility of 211
cases of C. difficile infection from 33 healthcare facilities was conducted. The results
found that the majority of patients had been treated with antibiotics in the previous
eight weeks prior to developing CDAD. 10% of the cases were community-associated
and 83% were health-care associated. The most common ribotypes identified were
027, 106, 078, 044,014 and 001 (Fenelon et al., 2009).

1.7

Risk factors for the development of CDAD

There are a number of identifiable risk factors known to increase the likelihood of
colonisation and development of CDAD.

The most common risk factors are

exposure to antibiotics, advanced age and hospitalisation. Other factors which are
attributed to increased risk are; recent gastrointestinal surgery or procedures,
immunosuppressive therapy, severe underlying disease, use of enteral tube feeding
(ETF) and proton pump inhibitors (PPIs) (Bignardi, 1998).
1.7.1 Antibiotics
There are multifactorial mechanisms by which antibiotics lead to increased
susceptibility to the acquisition of C. difficile.

Antibiotics destabilise the GIT

microflora and can alter the integrity of epithelial surfaces (Levy, 2000). In addition,
they increase peristalsis by acting as colonic irritants. The extent to which they affect
colonic microflora depends on the composition of the original microflora, the
spectrum of activity and dosage of the antibiotic, the route and duration of
administration and concentration of the active drug in the GIT. The most commonly
reported antibiotics implicated in the development of CDAD are clindamycin,
cephalosporins and fluoroquinolones (Bartlett, 1992). CDAD usually begins 4-9 days
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after the antibiotic therapy has stopped but it can occur up to eight weeks post
treatment (Rohde et al., 2009). Approximately 5-30% of patients receiving
antibiotics, particularly broad spectrum antibiotics, develop diarrhoea either during
the course of treatment or up to two months after the course finished (Hogenauer et
al., 1998).
1.7.2 Hospitalisation and length of stay
The risk of developing CDAD is highly correlated with the length of hospital stay
(Clabots et al., 1992). This is most likely due to the increased risk of exposure to
spores while in hospital (Imhoff & Karpa, 2009). The hands of health care workers
contaminated with C. difficile spores are the most probable vehicle for the spread of
spores during non-outbreak periods (Fekety et al., 1981; McFarland et al., 1989).
Spores of C. difficile are resistant to alcohol and standard hospital germicides (Wult
et al., 2003a). To limit the spread of CDAD a number of infection control measure
are required, these include; staff education, use of patient isolation, protective
clothing, hand hygiene, environmental clean cleaning of medical equipment and good
antibiotic stewardship (Vonberg et al., 2008).
1.7.3 Increasing age
Older age is considered a risk factor for the acquisition of C. difficile. A Swedish
group reported that the rate of CDAD per 100,000 persons older than 65 years was 20
times higher than that in persons younger than 20 years of age (Karlstrom et al.,
1998). Factors which are thought to be involved in the increased risk include agerelated changes in faecal flora, immune system dysfunction or more severe
underlying disease.
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Studies have shown a decrease in the level of beneficial and protective bacteria in the
GIT in later life, and an increase in species diversity (Woodmansey, 2007). There is
a decrease in the number of bifidobacteria with increasing age (O’Connell, 2009).
Bifidobacteria are capable of inhibiting the growth of many pathogenic bacterial
species; and any reduction in the number of beneficial bacteria increases the risk of
growth of pathogenic organisms. Such alterations in GIT microflora with age could
result in a reduced functionality and immune responsiveness in the gut and increase
susceptibility to infections (Woodmansey, 2007). Weakening of the immune system
also occurs with increasing age, and this can increase susceptibility to infection.
There is a reduction in the production of antibodies and T-cells. Natural killer (NK)
cells may also be reduced in number and activity (Takeda & Okumura, 2007).
1.7.4 Intensive care setting
Being a patient in ICU is acknowledged to be an independent risk factor for the
development of CDAD (Bignardi, 1998). Patients admitted to ICU are bed-bound,
have more severe underlying disease and decreased bowel motility.

They are

generally mechanically ventilated, receiving narcotics and at risk of developing
bowel ischemia. A decrease in bowel motility may allow those colonised with C.
difficile to develop colitis by increasing the exposure time of the toxin to its receptor
(Modena et al., 2005).
1.7.5 Proton pump inhibitors (PPIs)
Dial et al., (2007) estimated that the increased risk of developing CDAD with current
use of PPIs is 2.9 (95% CI 1.6-3.4). Gastric acid production is a key host defence
mechanism. PPIs inhibit an individual’s defence against ingested bacteria by
reducing the acidity of the gastric contents. C. difficile spores are resistant to acid,
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but vegetative cells are easily killed by gastric acid, reducing inocula by 99%. A
study by Jump et al., (2007) found forms of C. difficile survived exposure to gastric
contents if the pH was greater than, or equal to, five. There is also risk of recurrent
CDAD with the use of PPIs therapy. Patients receiving PPIs have been found to be
4.17 times more likely to have recurrence when compared to their counterparts not
receiving PPIs (Cadle et al., 2007).
1.7.6 Pre existing illness
The suggestion that pre-existing mucosal injury pre-disposes to C. difficile
colonization is supported by the fact that patients with inflammatory bowel diseases
(IBD) are at greater risk of acquiring CDAD than the general population (Issa et al.,
2007). Two recent retrospective studies have reported a two - to threefold increase in
the frequency of C. difficile infection in patients with IBD over a five to six year
period (Issa et al., 2007; Rodemann et al., 2007). These patient groups are exposed
to many of the risk factors for CDAD. They are often prescribed antibiotics for
treatment of other gastrointestinal pathogens and require frequent hospitalization for
management

of exacerbations

of their

IBD.

In addition,

many take

immunosuppressive medications. CDAD in patients with IBD carries a higher risk of
mortality than in patients without underlying IBD (Hookman & Barkin, 2009). A
recent multivariate analysis reported that patients with IBD and C. difficile had a
fourfold higher mortality than patients admitted to hospital with IBD or C. difficle
alone. Higher mortality, more frequent endoscopy and surgery were found in patients
with ulcerative colitis compared to Crohn’s disease (p < 0.05) who had associated C.
difficile (Ananthakrishnan et al., 2008).
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1.7.7 Enteral tube feeding (ETF)
C. difficile can be a cause of diarrhoea during enteral tube feeding. One prospective
cohort study of residents in a long term care facility demonstrated that ETF was an
independent risk factor for C. difficile colonisation (Odds Ratio 6.5, p = 0.006)
(Simor et al., 1993). A prospective cohort study to determine the incidence of C.
difficile acquisition and CDAD in tube fed and non-tube fed patients was conducted
by Bliss et al., (1998) Seventy-six patients receiving enteral tube feeding were
matched for age, ward and disease severity with 76 patients not on enteral tube
feeding. Acquisition of C. difficile was significantly greater in tube fed patients (p =
0.03) and more tube fed patients developed CDAD (p = 0.03). In this study, both
patient groups were on high levels of antibiotics.
There are a number of proposed reasons for the association of CDAD with ETF.
Firstly, enteral feeding provides a high frequency portal for inoculation of C. difficile
spores deep into the gut (O'Keefe, 2010). Environmental factors have been proposed,
as spores may be passed from the contaminated hands of healthcare workers during
manipulation of the tube feeding system and following inadequate hygiene measures.
There may also be contamination if decanting of formula is required, in the absence
of adequate quality control protocols.

The method of administration of enteral

feeding may also play a role, with post-pyloric feeding increasing the risk, as feed is
delivered below the gastric acid barrier and this may facilitate the introduction and
survival of C. difficile organisms. Bliss et al., (1998) reported that the incidence of
CDAD was greater in tube fed patients who received post-pyloric tube feeding at
some time during the study when compared to those who received pre-pyloric feeding
continually or those without a feeding tube. It should also be noted that patients who
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require enteral feeding, in particular those requiring post-pyloric feeding are usually
sicker patients with a higher rate of complications and are more often on antibiotics.

1.7.8 Other risk factors
Cancer chemotherapy is another risk factor for the development of CDAD. The
antimicrobial activity of several chemotherapeutic agents being thought to be the
causative factor (Anand & Glatt, 1993). Increased risk is also thought to be linked to
the immunosuppressive effects of neutropenia (Gorschluter et al., 2001). CDAD
mortality rates are higher for Caucasian than other ethnic/racial groups. This has
been attributed to the increased access to healthcare by elderly white people and to
the fact that they are more likely to receive treatment with antibiotics and, as a result
are at increased risk of developing C. difficile (Redelings et al., 2007).

1.8

Treatment for CDAD

There is no treatment required for asymptomatic carriers of CDAD (Johnson et al.,
1992). For those who are symptomatic, the first approach in their treatment should
be, if possible, discontinuation of the precipitating antibiotic(s). It has been shown
that 15-23% of CDAD will resolve with the discontinuation of antibiotics (Teasley et
al., 1983; Olson et al., 1994) . Supportive therapy with replacement fluids and
electrolytes may be required depending on disease severity. Antiperistaltic agents
should be avoided as, theoretically, they can increase the risk of precipitating toxic
megacolon by slowing the clearance of C. difficile toxin from the intestine (Aslam et
al., 2005; Bouza et al., 2005).

Metronidazole, vancomycin, teicoplanin and

bacitracin have been used to treat CDAD. These antibiotics are known to inhibit C
difficile growth and toxin production (Bricker et al., 2005). Most cases will respond
to metronidazole or vancomycin and will show improvement of symptoms within one
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to two days of starting therapy (Gerding, 2005). Treatment for ten days is indicated
for mild CDAD (HPSC, 2008). Approximately 78-97% of patients treated for an
initial infection will respond positively (Sunenshine & McDonald, 2006). However,
in some cases, the C. difficile spores can remain in the gut even after aggressive
treatment. Spores that remain hidden within the colonic diverticula can avoid gut
peristalsis and antibiotic treatment (Tedesco et al., 1985).
With the emergence of the B1/NAP1/027 strain and its associated increased
virulence, interest in the disease has increased. Investigation into methods of
preventing and treating the disease has intensified.

A number of emerging

therapeutic options for CDAD treatment are being developed. Medications used to
treat other infections are being studied as alternatives to metronidazole and
vancomycin. Due to the evidence that increased risk of recurrent CDAD is associated
with poor host humoral response (Wilcox, 2004), the use of intravenous
immunoglobulins to treat severe or refractory CDAD has had some promising results.
For prevention of the spread of the bacterium, sporicidal cleaning agents have been
developed. Probiotics are another of the options that are being studied for their role
in both prevention and treatment of CDAD.

18

Part 2 – The prevalence of malnutrition in patients who
develop Clostridium difficile associated disease
1.9

Malnutrition

Malnutrition is commonly defined as, ‘a state in which deficiency, excess or
imbalance of energy, protein and other nutrients causes adverse effects on body
form, function and clinical outcome’ (Stratton et al., 2003). In recent years, there has
been a greater understanding of the pathophysiology of malnutrition associated with
disease or injury which is commonly observed in the clinical setting. The presence
of inflammation results in an alteration of nutrient requirements, with the acute phase
response resulting in an increase in energy expenditure and nitrogen excretion.
Anorexia often accompanies inflammation and promotes further loss of lean tissue if
nutritional intake is inadequate. In critical illness or injury, an acute inflammatory
response occurs which has a rapid catabolic effect on lean body mass (Hill et al.,
1997). In the chronic disease state, the loss of muscle mass and function occurs at a
slower rate over a longer period of time.
Representatives from the international clinical nutrition support community formed
an International Guideline Consensus Committee and developed three aetiologicallybased terms for the diagnosis of malnutrition in adults in the clinical setting. In
chronic starvation without inflammation, the term ‘starvation-related malnutrition’
should be used. ‘Chronic disease-related malnutrition’ is the term recommended
when chronic disease and mild to moderate inflammation are present. ‘Acute disease
or injury-related malnutrition’ should be used when inflammation is acute and of a
severe degree (Jensen et al., 2010).
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1.10

Malnutrition in the clinical setting

In health care facilities, there is evidence that malnutrition is present in 15-60% of
patients (Stratton et al., 2003; Sorensen et al., 2008). Variation in prevalence data
occurs because of different methods of nutritional assessment and different patient
groups studied (Elia et al., 2005a). Irish data show that 11% of a mixed group of
surgical and medical patients were malnourished (Corish et al., 2000). The most
recent information on the prevalence of malnutrition in patients in Irish hospitals
comes from the Nutrition Week Survey (NSW), conducted in January 2010. This
data collection was part of a wider BAPEN survey which has an ongoing aim to
obtain prevalence data on malnutrition. The Malnutrition Universal Screening Tool
(MUST) was carried out on all new admissions complying with specified inclusion
criteria

1,2

,over a specific three day period. The nutritional status of 1602 patients

was recorded in 29 hospitals and 17 care homes. One-third of patients were at risk of
malnutrition (33%); 25% were at high risk and 8% at medium risk. These Irish
results are very similar to those reported from the United Kingdom (UK) data (34%
in UK hospitals found to be at risk of malnutrition) (Russell & Elia, 2011).
Malnutrition was common in all types of hospitals, all types of wards, diagnostic
groups and at all ages.

Eighty-six percent of patients identified as at risk of

malnutrition were admitted directly from home suggesting that the risk of
malnutrition originates in the community (Russell et al., 2011).

1

Inclusion criteria for Nutrition Screening Week (NSW) BAPEN: all adult patients admitted to
medical, surgical, orthopaedic/trauma, care of the elderly, stroke and oncology wards between 00.01
hours on the 12th of January to 23.59 hours on the 14th of January 2010.
2
Exclusion criteria for NSW BAPEN: patient under 18 years of age, already established on nutrition
support (oral nutritional supplements, Percutaneous Gastrostomy (PEG) feeding or Parenteral
Nutrition)
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1.11 The prevalence of malnutrition and CDAD
A number of the risk factors associated with the acquisition of C. difficile are also the
risk factors associated with malnutrition.

There is limited information in the

literature on the prevalence of malnutrition in patients with CDAD. One study
assessed prevalence of malnutrition using MUST in 76 patients at time of diagnosis
of CDAD. In this group, 57% of the patients were malnourished (MUST score of 2
or more) (Wong et al., 2008). No other studies have focused on the prevalence of
malnutrition in this patient group and there are no Irish data available, although it is
thought that prevalence is likely to be similar to that observed in the UK.

1.12

CDAD and risk factors for malnutrition

1.12.1 Increased age
As previously discussed, one of the risk factors for the acquisition of C. difficile is
increased age. Although not observed in the recent Irish study (Russell & Elia,
2011), some studies have shown that elderly patients are more at risk of malnutrition
than younger patients (McWhirter & Pennington, 1994). A number of reasons have
been identified that contribute to the changes in body weight and composition of the
elderly and which can result to the development of malnutrition. Physiological
changes include age-related changes to the GIT. Selective neurodegeneration of the
ageing enteric nervous system, resulting in symptoms of dysphagia, reflux and
constipation, often occurs (Saffrey, 2004). Changes are also seen in the pancreas,
liver and small intestine with increasing age (Popper, 1986; Dreiling et al., 1991).
There is a reduction in overall energy intake and this can occur due to a decrease in
appetite and early satiety. Changes in satiety are a result of alterations to the GIT
sensory function. There is also an impairment of the receptive relaxation of the
gastric fundus, with rapid antral filling and distension (Morley, 2001). Daily food
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intake has been reported to decrease by up to 30% between the ages of 20 to 80 years
(Wurtman et al., 1988). The sense of smell is known to decline with age; this results
in a reduced intake and interest in food. Hormonal alterations and the increased
activity of cytokines are also linked to the anorexia that occurs with ageing.
Social factors such poverty, isolation and reduced ability to prepare and cook food
can all have an impact on the nutritional status of older people living in the
community setting (Ahmed & Haboubi, 2010). Dentition is often impaired with
increasing age. There can be loss of teeth and, in cases where dentures are worn, illfitting dentures will impact on oral intake (Nakanishi et al., 1999).
Changes occur to body composition over time; body fat increases with a decrease in
fat-free mass due to a loss of skeletal muscle (Prentice & Jebb, 2001). The increase
in body fat with increasing age is related to reduced physical activity, reduced
growth hormone secretion, diminished sex hormones and reduced resting metabolic
rate observed in older people (Ahmed & Haboubi, 2010).
1.12.2 Length of hospital stay
A further risk factor to the development of malnutrition is length of hospital stay.
Studies have shown that during a hospital admission, a patient’s nutritional status
deteriorates and, as a result, those with a longer hospital stay are at increased risk of
malnutrition.

Several studies have found evidence to suggest that hospitalized

patients receive less than optimal nutritional care due to lack of training and
awareness of malnutrition among hospital staff (Dupertuis et al., 2003). During a
hospital stay, patients are frequently placed nil per os (NPO) without being
artificially fed, and this can occur on multiple occasions. Patients may undergo
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procedures prior to, or during, meal service resulting in interruptions and/or missed
meals, and meals can often be considered unpalatable.
Mc Whirter and Pennington (1994) investigated changes in nutritional status in
general surgical and medical patients that occurred from hospital admission to
discharge.

Their study showed that 40% of patients were undernourished on

admission. A further assessment on discharge indicated that a mean weight loss of
5.4% occurred as did a gradual decline in nutritional status in 14% of overweight,
26% of

mildly malnourished and 37% of moderately malnourished patients.

Braunschweig et al., (2000) observed a 31% decline in nutritional status from
admission to discharge.

Naber et al., (2004) investigated nutritional status on

admission to, and discharge from, hospital using three methods of nutritional
assessment including the Subjective Global Assessment (SGA).

Using this

classification, 45% of patients were classified as malnourished on admission and
51% were classified as malnourished on discharge. In a study carried out in patients
admitted to two Dublin teaching hospitals, weight loss during the hospital stay
occurred in 65% of the overweight and obese, 66% of normal weight and 43% of the
underweight patients (Corish et al., 2000). It is difficult to compare these studies
adequately due to the different methods of nutritional assessment used but overall,
they indicate that the nutritional status of patients in hospital deteriorates during their
period of hospital admission.
1.12.3 Enteral tube feeding (ETF)
As with older age and length of stay, the use of ETF is also associated with patients
who are malnourished or at risk of malnutrition. ETF is used to feed patients who
cannot attain adequate oral intake from food and/or oral nutritional supplements or
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who cannot eat/drink safely. The National Institute of Clinical Excellence (NICE)
guidelines (2006) state that healthcare professionals should consider ETF in people
who are malnourished or at risk of malnutrition and have inadequate or unsafe oral
intake and a functional, accessible gastrointestinal tract. Nutrition support should be
considered in people who are malnourished as defined by any of the following:


A Body Mass Index (BMI) less than 18.5 (kg/m2);



Unintentional weight loss greater than 10% in the last 3-6 months;



BMI less than 20 (kg/m2) and unintentional weight loss greater than 10%
within the last 3-6 months.

NICE also provide guidelines for the introduction of nutrition support in people at
risk of malnutrition, defined as follows:


Have eaten little or nothing for more than 5 days and/or are likely to eat
little or nothing for the next 5 days or longer;



Have poor absorptive capacity and/or have high nutrient losses and/or
have increased nutritional needs from causes such as catabolism.

In summary, ETF is used in those patients who are sicker and are at risk of
malnutrition or who are malnourished.

1.13

Impact of malnutrition

Malnutrition is known to predispose to disease and adversely affect outcome. It has
detrimental effects on both physical and psychological health (Stratton et al., 2003a).
Malnutrition has been associated with higher rates of complications, and this has
been shown in a number of studies as summerised in Table 1.1. These complications
are associated with higher hospital costs (Messner et al., 1991; Correia & Waitzberg
2003) higher mortality (Coats et al., 1993; Correia & Waitzberg, 2003) and longer
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hospital stay (Coats et al., 1993; Correia & Waitzberg, 2003). In the UK, the cost of
malnutrition was calculated to be responsible for over 10% of the total health care
budget. This is twice the amount that is spent on obesity and its related comorbidities (Elia & Stratton, 2009). In Ireland, the cost of malnutrition on the health
budget was calculated to be 10% of the €13.8 billion budget (Rice, 2010).
Table 1.1 Physical and psychosocial effects of malnutrition
Adverse effect of malnutrition

Consequence

Impaired immune response

Predisposes to infection

Reduced muscle strength and increased Inactivity, inability to work effectively
fatigue
and poor self care
Reduced respiratory muscle strength
Inactivity, especially
individuals

Poor cough pressure

in bed bound Predisposes to pressure ulcers and
thrombo embolisms

Impaired thermoregulation

Hypothermia

Impaired wound healing

Increased wound infection, prolonged
recovery from illness and increased
length of hospital stay

Impaired psycho social function

Apathy, depression, self neglect

Source: Adapted from The “MUST” Report (Elia, 2003)

1.14

Nutritional screening

Nutritional screening is an assessment to identify those at risk of malnutrition and
who require further nutritional assessment.

All nutritional organisations and

healthcare accrediting groups agree that nutrition screening is essential. It identifies
those patients who are at nutritional risk so that appropriate nutritional assessment
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and intervention can occur. Nutrition screening tools try to incorporate objective and
subjective parameters that are sensitive to changes in nutritional status. It is accepted
that no single marker is adequate and numerous factors have to be taken into account.
There is no universal agreement on the best method of performing nutritional
screening.

Currently, many different measures are used, either alone or in

combination, to gather information about an individual’s nutritional status. Green
and Watson (2006) identified over 70 tests and tools to detect malnutrition. It is also
believed that many unpublished screening tools are being used in the clinical setting.
A number of the published screening tools have been critically reviewed and their
advantages and disadvantages identified.

Those commonly used are the SGA

(Detsky et al., 1987), the Nutritional Risk Screening Tool (2002) – NRS 2002
(Kondrup et al., 2003a), the Mini Nutritional Assessment (MNA) (Guigoz et al.,
1994) and MUST (Elia, 2003).
The European Society of Parenteral and Enteral Nutrition (ESPEN) guidelines for
nutritional screening recommend MUST, NRS-2002 and MNA (Kondrup et al.,
2003b). Of the 29 Irish hospitals that participated in NSW (2010), 28% were using
MUST and a further 6% were using MUST with the MNA or a local tool. Only 3%
were using the MNA alone (Russell et al., 2011).
1.14.1 Malnutrition Universal Screening Tool (MUST)
MUST is the screening tool with the strongest support in the UK and Ireland. It is
recommended as a screening tool by NICE, BAPEN and the British Dietetic
Association (BDA). In 2008, the Irish Department of Health and Children strongly
supported the use of MUST in Irish hospitals in the guideline document “Food and
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nutritional care in hospitals, guidelines for preventing under-nutrition in acute
hospitals” (Department of Health and Children, 2008).
MUST has been developed to detect protein-energy malnutrition and the risk of
developing malnutrition using evidence based criteria (Elia, 2003).

The three

independent criteria used are; BMI, unintentional weight loss and acute disease effect
producing or likely to produce no nutritional intake for greater than five days.
Together, the three components are better predictors of outcome than the individual
component (Elia, 2003). MUST has content validity (comprehensiveness of the
tool), face validity (issues that are relevant to the purpose of the test) and internal
consistency (Wood et al., 2004; Stratton et al. 2006). It has been shown to have
predictor validity in the hospital setting for length of hospital stay, mortality and
discharge destination. In the community setting, it has predictive validity for general
practitioner visits and hospital admission in free living individuals (Stratton et al.,
2002, Elia, 2003).

It has excellent reproducibility between users in different

healthcare settings across the UK (Elia, 2003) and has been shown to have excellent
agreement with a dietitian’s assessment of malnutrition (Elia, 2003). In comparison
with a number of other screening tools, MUST has been found to have “fair to good”
to “excellent” concurrent validity (Elia et al., 2005a).
1.14.2 Mini Nutritional Assessment (MNA)
The original MNA was developed to provide a simple and reliable way to screen the
nutritional status of persons over 65 years and to add a nutritional component to a
comprehensive geriatric assessment. MNA screening is likely to identify risk of
developing undernutrition at an early stage since it includes questions about physical
and mental health which frequently affect the nutritional status of elderly. It is a
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combination of a screening and an assessment tool. The predictive validity of MNA
has been evaluated by demonstrating its association with adverse health outcomes
(Ek et al., 1996), social functioning, mortality and higher rates of visits to the GP
(Anderson et al., 1984; Berner, 2003). The tool has been validated specifically for
the elderly (Guigoz et al., 1996) and has been found to be sensitive and reliable
(Gazzotti et al., 2000; Bleda et al., 2002; Holm & Soderhamn, 2003). However
MNA has a low efficacy with regard to predicting future malnutrition or adverse
health outcomes for older people when screened at baseline (Rasmussen et al., 2010).
In 2001, the short form MNA (MNA –SF) was developed based on the original
MNA. It was developed as a standalone screening tool and identifies malnutrition
using 6 questions. The MNA – SF has been found to have 98% sensitivity, 100%
specificity and 99% diagnostic accuracy for predicting malnutrition (Kaiser et al.,
2009).
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Part 3 - Probiotics and Clostridium difficile associated
disease
1.15 Functional Foods
Probiotics, prebiotics and synbiotics are classified as a group of foods called
‘Functional Food’ (FF).
“A food can be regarded as ‘functional’ if it satisfactorily demonstrates to
affect beneficially one or more target functions in the body, beyond adequate
nutritional effects, in a way that is either an improved state of health and
wellbeing and/or reduction of risk of disease” (Diplock et al., 1999).
FF must remain a food, and it must demonstrate its effects in amounts that can be
normally consumed in the diet (Diplock et al., 1999).
1.15.1 Probiotics
Probiotics are live microorganisms that when administered in adequate amounts
confer a beneficial effect on their host, by improving microbial balance and exerting
health benefits beyond inherent general nutrition (FAO/WHO, 2001). The concept
of probiotics emerged from observations early in the 19 th century by the Russian
immunologist, Elie Metchnikoff.

He postulated that lactic acid bacteria offered

health benefits and promoted longevity. In recent years, knowledge of the role of
probiotics in health has increased. There is a growing body of scientific literature and
a rise in the number of commercially available probiotic products. Numerous health
effects are now associated with probiotic use. While some of these are well
supported by evidence, probiotics are often used to treat conditions for which data
regarding their efficacy is lacking or conflicting (Williams, 2010).
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1.15.2 Prebiotics
Prebiotics are “selectively fermented ingredients that allow specific changes in both
the composition and/or activity in the GIT microflora that confers benefit upon a
host’s wellbeing and health” (Gibson et al., 2004). Fermentation of the prebiotics by
endogenous anaerobic microorganisms occurs in the colon. Short chain carboxylic
acids and lactic acid are produced and, these in turn, provide metabolic substrates for
the colonocytes.
Prebiotics can occur naturally in foods or be added to food products. The common
prebiotics include inulin, fructo-oligosaccharides (FOS), galacto-oligosaccharides
(GOS),

soya-oligosaccharides,

xylo-oligosacchardies,

pyrodextrins,

isomalto-

oligosaccharides and lactulose. The majority of studies have used FOS, GOS and
inulin which have a long history of safe use. The reported benefits of prebiotics are
still in the early stage of investigation but their efficacy has been examined in
conditions such as constipation, diarrhoea, osteoporosis, obesity and type II diabetes
mellitus (Roberfroid, 2000).
1.15.3 Synbiotics
Synbiotics are a mixture of prebiotics and probiotics. They beneficially affect the
host by improving the survival and implantation of the live microbial dietary
supplements in the GIT (Gibson et al., 2004). It is thought such products can
potentially offer the properties of both probiotics and prebiotics. Some researchers
feel that synbiotics should be more than a mixture of the two ingredients; that a
synergy must exist between the ingredients (Jardine, 2009). To date most of the
research has been on probiotics and prebiotics individually and there is less
information about synbiotics.
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1.16 Mechanism of action of probiotics
The mechanisms of action of probiotics remain an area of research. Many of the
effects have been studied and established in animal models or in vitro assays. In
humans, the direct demonstration of the effects of probiotics on relevant biomarkers
is still incomplete (Rijkers et al., 2010).

There are a number of proposed

mechanisms through which probiotics could have an effect. Many have been shown
to inhibit the growth and development of pathogenic bacteria, alter the composition
of the GIT microflora and modulate the innate immune system. The suggested
mechanisms for their effects on human health are proposed to be:


Competitive inhibition of other organisms through competition for
fermentable substrates and adhesion sites within the gut;



Lowering gut pH through production of organic acids;



Production of bacteriocins;



Stimulation of the immune system;



Regulation of gut motility;



Strengthening gut barrier function;



Binding and metabolism of toxic substances;



Release of gut protective metabolites.

(O’Connell, 2009)

1.17 Probiotic availability
A probiotic is defined by its genus (e.g. Lactobacillus), its species (e.g. rhamnosus)
and strain designation (often a letter or a number e.g. GG). Frequently, product
manufacturers will generate a consumer friendly name; these names may be
trademarked (™) or be a registered trademark (®) and are not the scientific name.
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The FAO/WHO has a number of criteria that must be met for an organism to be
classified as a probiotic. The organism must be characterised to strain level using
phenotypic and genotypic techniques. There must be proof that the probiotic strain is
safe for human consumption and is not contaminated in the form in which it is
delivered. There should be evidence of its functional efficacy from in-vivo studies
using animals and humans (FAO/WHO, 2002).
Probiotics are available in a wide range of commercial forms; capsules of freeze dried
or lyophilized cultures, heat dried culture supernatants and mixed into dairy and other
foods. They are available as a combination of organisms of varying quality and
viability. The majority of commercial cultures for the food industry contain either
Lactobacillus species or Bifidobacterium species. Some Escherichia. coli (E. Coli)
species, Bacillus species and yeasts are also used. In the last few years, the range of
food products containing probiotics has increased considerably. Products are
available in supermarkets, in health foods stores and on the internet.

Europe

traditionally has a strong position in the probiotic food market. In 1997, probiotic
yogurts and milk accounted for 65% of the European FF market, with a market value
of $889 million (Young, 1998). Daily dose dairy probiotic drinks are the largest
growing probiotic product type in the European market (Saxelin, 2008). In Europe,
Lactobacillus rhamnosus GG (L. rhamnosus GG) appears to be the most widely used
probiotic on the food market. L. rhamnosus GG containing foods are available in at
least 15 European countries under various brand names (Saarela, 2009).

1.18

Commonly used probiotics

The most common probiotic genii used in food and in clinical trials are the bacteria
Bifidobacteria and Lactobacilli and the yeast Sacharomyces boulardii.
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Yeast

probiotics differ from bacterial probiotics in physiological structure, size and their
impact on antibiotics, with yeast not being affected by antibiotics (Czerucka et al.,
2007).
1.18.1 Bifidobacteria
Bifidobacteria are gram positive polymorphic rods. They are non-spore forming,
non-motile and catalase-negative bacteria (O’Connell, 2009). Bifidobacteria have
been widely used in food products for the past twenty years. There are upwards of 30
species of bifidobacteria identified (Leahy et al., 2005). They have been isolated
from many sources such as sewage, human and animal faeces, and the rumen of
cattle, dental caries and honey bees (Felis & Dellaglio, 2007). Bifidobacteria account
for 3-6% of microflora in the GIT and are considered as key commensal bacteria in
human microbial interactions, playing a pivotal role in a healthy GIT (Benno et al.,
1984; Satokari et al., 2003). The proportion represented by bifidobacteria species
varies between individuals and depends on lifestyle factors such as diet, exercise and
stage of life. The dosage of bifidobacteria in food or other products can depend on the
method of administration. The scientific literature appears to support a minimum
probiotic dosage of 109 colony forming units (CFU) per day if a measurable benefit to
the host is to be observed (O’Connell, 2009).
1.18.2 Lactobacilli
Lactobacilli are gram positive, non-spore forming, catalyse-negative, usually nonmotile and typically nitrate-reducing, rod-shaped bacteria.

They utilise glucose

fermentatively and may be homofermentative, thereby producing lactic acid from
glucose or they may also be heterofermentative i.e. they can produce lactic acid,
carbon dioxide, ethanol and/or acetic acid (Saarela, 2009). Their production of
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organic acids and resultant lowering of pH gives them an advantage over other
microbes (Saarela, 2009). In 2008, the number of lactobacilli species identified was
around 120 (Saarela, 2009). However, this number is continually changing as new
species are identified or some species are merged to form subspecies or transferred
into another genus. Some species and strains are broadly used as starters and adjunct
cultures to drive food and feed fermentation and have been used for thousands of
years for this purpose. The notable products are dairy products (cheese and yogurts),
fermented vegetables (olives, pickles and sauerkraut), fermented meats (salami and
sausages), sourdough breads and other cereal-based commodities.
L. rhamnosus GG has received the most clinical attention to date. L. rhamnosus GG
was discovered in 1985 by natural selection of healthy human microflora using the
ideal characteristics of a probiotic (Silva et al., 1987). L. rhamnosus GG has been
shown to secrete a low molecular weight compound that inhibits a broad spectrum of
gram positive and negative bacteria and anaerobic bacteria (Silva et al., 1987). It has
been shown to inhibit the attachment of E. coli, Klebsiella pneumonia and
Pseudomonas aeruginosa to uroepithelial cells and intestinal epithelial cells (Chan et
al., 1985; Mack et al., 1999). It has also been found to suppress bacterial enzyme
activity (Gorbach, 2000).
1.18.3 Saccharomyces boulardii (S. boulardii)
S. boulardii is the most common yeast used as a probiotic. Since its discovery in the
1920s by a French microbiologist, Henri Boulard, it has been used as a probiotic in
Europe and has been investigated in clinical trials worldwide. S. boulardii is not
endogenously found in the GIT of humans (Imhoff & Karpa, 2009). It has an
optimum growth temperature of 370C, is resistant to low pH and is tolerant to bile
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acids (Fietto et al., 2004; Graff et al., 2008a; Pardo et al., 2009). Survival at this
temperature makes it one of the few types of yeast able to live at human body
temperature. S. boulardii is resistant to antibacterial agents and survives gastric
acidity (Graff et al., 2008a; Buts, 2009).
S. boulardii is administered in capsules of lyophilized or heat dried product. When S.
boulardii is given orally, it achieves a steady state concentration within three days
and is cleared within three to five days following discontinuation (Blehaut et al.,
1989; Elmer et al., 1999; Graff et al., 2008b). Lyophilized S. boulardii is distinct
from dietary probiotic products and could be considered an example of a “probiotic
drug”(Czerucka et al., 2007).
Studies in animals and cell models indicate S. boulardii has beneficial effects against
a number of pathogenic toxins, preserves cellular physiology, interferes with
pathogen attachment or assists in re-establishing short chain fatty acid (SCFA)
levels. It may also act as an immune regulator both within the GIT lumen and
systemically (McFarland, 2010). Castagliuolo et al., (1999) reported that 54 kDa
serine protease produced by S. boulardii directly degrades C. difficile toxins A and
B. It also produces proteases capable of degrading C. difficile toxin A and B receptor
sites on the cell surfaces of enterocytes unlike any other strains of Saccharomyces
(Pothoulakis et al., 1993; Castagliuolo et al., 1999). It has been proposed that once
the toxin receptors have been acted upon by the protease, C. difficile is unable to
produce disease as the bacterial toxins cannot attach to the inactivated receptor sites.
This yeast may also stimulate chloride absorption and modulate C. difficile toxin B
levels thereby reducing the symptoms of CDAD and permitting the re-establishment
of normal GIT microflora. It is proposed that there has to be clearance of C. difficile
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before there can be inactivation of toxin receptor sites by S. boulardii (McFarland et
al., 1994; Imhoff & Karpa, 2009). Two studies have shown S. boulardii has an
effect on the immune system resulting in up-regulation of total and specific antitoxin A secretory IgA expression in animal models of CDAD (Buts et al., 1994;
Qamar et al., 2001). These actions of S. boulardii have lead to a number of trials
investigating the role of the yeast in CDAD.

1.19

Dosage of probiotics

Commercially available products typically have at least 10 6 CFU but may have as
many as 1012 CFU (Verna & Lucak, 2010). Probiotics have a limited lifespan and, as
a result, repeated dosing is needed to achieve constant concentrations within the GIT.
One week after the discontinuation of oral probiotics, there are no longer detectable
amounts in the stool (Spiller et al., 2008).
Confusion occurs among the general public and health professionals as to which
probiotics are best for good health. The wide range of probiotic strains in
commercially available products and the quality control of probiotics are some of the
reasons why confusion arises. Also, there is no consensus on the effective dosage of
probiotics. In clinical trials, doses have varied from 107 to 1011 per day. In most
studies using the bacteria lactobacilli, the dose typically used ranged from 1-20
billion colony forming units per day (Williams, 2010). In the clinical trials with the
yeast S. boulardii, the dose ranged from 250 to 300 mg per day for durations of
between three days and six months (McFarland, 2010). In addition, different
probiotic species and genii may have different immunological and physiological
effects in various disease states (Verna & Lucak, 2010). In products providing a
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combination of probiotics, the probiotics may interact and have a different impact on
host intestinal microflora than if given as a single probiotic preparation.
As probiotics contain live organisms, the administration of antibiotics together with
probiotics could kill a large number of the organisms and, as a result, reduce the
efficacy of the probiotics (Williams, 2010). It has been recommended that patients
consume bacteria derived probiotics separately from antibiotics, leaving at least a
two hour gap between consumption. Anti-fungal medications may also interact with
yeast probiotic products and reduce their efficacy (Williams, 2010).

It is

recommended by one commercial manufacturer that S. boulardii should not be taken
with any oral systemic anti-fungal medications (Williams, 2010).

1.20

Regulation of probiotics

The regulation of probiotics depends on how they are to be consumed, for example
whether they are included in a food, used as a dietary supplement or sold as an over–
the-counter or prescribed medication. Within Europe, there are no defined lists of
compounds that are accepted for use as prebiotics or probiotics. Quality assurance
can also vary with the type of product, indication for use and country in which the
product is sold. If the product makes a claim promising a health or nutritional
benefit, this is regulated by European legislation. The legislation 2000/13/EC
prohibits a company from stating that a foodstuff has the properties to prevent, treat
or cure human disease or from making reference to any such properties.

The

regulation 2006/1924/EC on Nutrition and Health claims allowed on food products
permits only standardised nutritional claims or specifically authorised health claims
to be made. This regulation provides consumer assurance that misleading claims
cannot be made. When a health claim is made, the format of the nutritional label is
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specified in accordance with article 4(1) of Directive 90/496/EC. In Ireland, the
Food Safety Authority of Ireland (FSAI) is responsible for the enforcement of all
aspects of food legislation, including food labelling.

1.21

The variation of probiotics products

For optimal probiotic functionality, the probiotic product should contain sufficient
quantities of the specific probiotic strain throughout the storage period until
consumed. The pH, storage temperature and exposure to other microbes all impact
on the viability and stability of the probiotic strain in a food product. How the
products are manufactured may significantly affect the potency of the probiotic over
time. Lyophilized products are stable at room temperature for one year provided
they are protected from moisture (Graff et al., 2008a). Products containing heat
dried probiotics must be refrigerated.

All probiotic products should be stored

according to manufacturers’ guidelines and all have a limited shelf life. Probiotic
supplements produced by different manufacturers differ widely.

Even the same

product produced by the same manufacturer may vary due to the combination of
probiotics they contain and bioactivity at the time of production.
Concerns have been expressed regarding the accuracy, quality and quantity of
probiotic products available on the market.

A number of studies have been

conducted that illustrate the difficulties with product stability and labelling despite
the legislation that exists to protect consumers. A gradual reduction in viable cell
count occurs in probiotic products regardless of the producer’s expiry date, calling
into question the accuracy of expiry dates on probiotic containers (Jayamanne &
Adams, 2006). A study examined 58 probiotic products from Europe, the UK,
Canada, Asia and Japan. Only 38% contained the dose described on the label and
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29% did not contain strains listed on the label (Masco et al., 2005). A further study
using polymerase chain reaction reported that two of five products tested contained
no bifidobacteria and two of the products contained Lactobacilli that were not
included on the product label (Drisko et al., 2005). A review of brewer’s yeast found
the tablets contained no viable yeast at all (Sargent & Wickens, 2004). Marcobel et
al., (2008) tested 14 commercial probiotic products and many of the probiotic
products contained unadvertisied additional lactobacilli and bifidobacteria, whereas,
others were missing species listed on the product label.

These findings would

indicate that the manufacturers of probiotic products should be more tightly regulated
and consumers must be wary of the product information on the products they are
consuming.

1.22

Safety of probiotics

The safety of probiotics generally relates to the fact that they contain living
organisms. Potential risks include transfer of antibiotic resistant genes, translocation
of living organisms from the intestine to other areas of the body, persistence of the
probiotic in the small or large bowel or the development of adverse reactions relating
to interactions with the host microflora. The incidence of bacteraemia attributable to
probiotic strains remains extremely low (Salminen et al., 2002),the estimated risk of
developing bacteraemia from ingested Lactobacilli being less than 1 per million
individuals (Borriello et al., 2003). The typical adverse reactions reported in clinical
trials are mild to moderate nausea, vomiting, abdominal pain, cramps, rash, diarrhoea
and constipation (Kligler & Cohrssen, 2008). Constipation and increased thirst have
also been related to S. boulardii (Karpa, 2007) while the risk of developing
fungaemia from S. boulardii is estimated at 1 per 5.6 million users (Karpa, 2007). A
population based study in Finland found no increase in the number of cases of
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Lactobacillus bacteraemia despite a massive increase in consumption of a product
containing L. rhamnosus GG.

The incidence of Lactobacillus bacteraemia was

0.3/100,000 inhabitants per year over a 5 year period (Salminen et al., 2002;
Salminen et al., 2004).

Williams (2010) commented that the overall risk of

developing an infection from ingested probiotics is low, particularly in a generally
healthy population.
Boyle et al., (2006) suggest probiotics should be used cautiously in immune
compromised individuals including those in a debilitated state or with malignancies.
Caution should also be exercised in those with artificial heart valves, in patients with
a history of rheumatic heart disease and those with central venous catheters. Any
administration of probiotics to patients who are severely ill, in the intensive care
setting or who have central line catheters should be monitored closely for episodes of
unexplained fever (Buts, 2009).

Concern has been expressed about the use of

probiotics in pre-term infants (Boyle et al., 2006).

An increase in infectious

complications could also be anticipated should probiotics be administered by
jejunostomy, as this mode of delivery allows for an increase in the number of viable
bacteria in the small intestine, as by passing of the acidic contents of the stomach
occurs. Lactobacillus has been reported to cause bacteraemia in patients with short
bowel syndrome, possibly due to altered gut integrity (Kligler & Cohrssen, 2008).
Lactobacillus preparations are contra-indicated in patients with hypersensitivity to
lactose or milk (Kligler & Cohrssen, 2008) while S. boulardii is contraindicated in
patients with yeast allergy (Williams, 2010). Neither should it be taken with any
systemic oral antifungal products.

If patients are on antifungal medications, a
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staggered dosing regimen is suggested if a decision is made to use probiotics (Elmer
et al., 1995).

1.23

Consumer attitudes towards probiotics

Probiotics can be a very attractive option for patients for whom traditional
pharmacological therapies can be marginally effective and their disease/illness is
impacting on their quality of life. The current marketing of probiotic containing
foods, together with the widespread availability of probiotics, reinforces the
perception that probiotics are a ‘natural’ product. Individuals can commence this
alternative therapy without any advice from a medical professional.

However,

studies would indicate consumer knowledge about these products is variable.
A focus group of 100 consumers was used to assess attitudes towards the probiotic
cultures Lactobacillus and Bifidobacterium (Bruhn et al., 2002). Responses varied
from those who were knowledgeable to those who were “repulsed” and unaware.
Some individuals associated “culture” and “bacteria” with harmful bacteria and,
therefore, expressed concern with their use. A number of consumers believed that
probiotic cultures were unnecessary and a well balanced diet should provide the
necessary bacteria.

More detailed information on labelling and directions for

consumption and the possible side effects from over consumption of probiotics was
also raised as concerns by the group. In a Brazilian study, 34% of consumers defined
probiotics as foods that contributed to weight reduction only, 29% defined them as
foods that contributed to the intestinal environment while 21.5% of participants were
unaware of the benefits of probiotics. Overall, the authors considered that consumers
were confused about probiotic foods and their benefits (Vianna et al., 2008). A study
of a New Zealand population found 25.4% of a random sample of consumers had
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previously used probiotic products. The majority of the users had been recommended
probiotics by the media but other common sources who recommended the products
were friends and doctors (Schultz et al., 2011). A number of studies have found that
probiotic users have similar profiles. There are more likely to be female (Block et al.,
2007), educated (Block et al., 2007; Landstrom et al., 2007a), users of other non
prescription supplements (Landstrom et al., 2007a) and also of European origin
(Schultz & Lindstrom, 2008). From the perspective of the Irish population, a survey
of Irish consumers was conducted in 2000 by Bogue and Ryan. 90% of respondents
were aware of FF or the concept of FF. There was a high awareness of the benefits of
FF ingredients such as calcium, vitamin C and iron but consumers were less familiar
with the benefits of phytoestrogens, oligosaccharides and probiotics. Respondents
would be more likely to purchase FF if there was more detailed information about
the FF concept on the product label. As with previous studies of consumers, the
authors concluded that the consumers did not fully understand the concept of FF and
the associated benefits. Further qualitative research may help understand more about
consumers’ perceptions of health enhancing foods and the various health messages
generated by public health bodies (Bogue & Ryan, 2000).

1.24

Dietitians’ attitudes to probiotics

Dietitians are health professionals that assess, diagnose and treat, diet and nutrition
related problems at an individual and wider public health level. Dietitians use the
most up to date public health and scientific research on food, health and disease,
which they then translate into practical guidance to enable people make appropriate
lifestyle and food choices (BDA, 2010). Dietitians are the healthcare professional
most likely to educate consumers and assist in scientific research into the benefits
and effects of FF use (de Jong et al., 2004). They are in a key position to influence
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consumers to use or avoid FF. There is no study examining dietitians’ beliefs or
attitudes towards probiotics alone. There are a number of studies investigating their
attitude towards FF, the group of foods into which probiotics are classified. The
results from these studies have been mixed. An American study reported that in a
group of 162 dietitians there was a positive view of FF. More than 80% of dietitians
were confident about the effectiveness of FF in the prevention of illness and
treatment of chronic illness, and at least 89% were confident of their safety (Lee et
al., 2000). In a study of dietitians’, nurses’ and physicians’ trust in FF and their
willingness to recommend them, dietitians were more willing to recommend FF than
the other groups of health professionals studied. There was also greater trust and
interest in the FF products among the dietitians when compared to the other two
groups (Landstrom et al., 2007b). The need for scientific evidence for particular FF
before recommending them to clients was required by the dietitians in this study
however (Landstrom et al., 2007b).
In a Dutch study of dietitians, FF were considered useful only in specific cases with
defined health problems. However, the authors concluded that confusion existed
among dietitians about claims, safety, efficacy and the product handling aspects of
FF (de Jong et al., 2004). McConnon et al., (2004) studied the differences in
perception of FF between the public and nutritionists. There were some evident
differences with the consumer being more worried about the benefits and the
nutritionists being concerned over the control and responsibility of the products. An
Irish study found consumers and dietitians had a similar perception of FF, but
knowledge about FF was greater in the dietitians (Morrissey, 2007).
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1.25

Dietitians’ knowledge of probiotics and professional practice

In Dutch dietitians 57% had a limited knowledge of FF (de Jong et al., 2004). Two
thirds of a group of American dietitians were confident of the role of FF in the
maintenance of good health and prevention of chronic diseases, but fewer dietitians
were knowledgeable about the role in acute disease (Lee et al., 2000). The Dutch
dietitians got most of their information from journals, magazine articles or the
internet. Swedish dietitians got their information from scientific statements and the
food industry (Landstrom et al., 2007b). There were varying findings among the
groups on the practice among dietitians. Swedish dietitians were willing to
recommend FF to patients (Landstrom et al., 2007b). American dietitians
recommend FF for prevention rather than treatment (Lee et al., 2000). Nutritionists
in the UK were hesitant to recommend FF possibly due to the lack of scientific
evidence supporting some products (McConnon et al., 2004).

1.26 CDAD and probiotics
From a review of the mechanistic actions of probiotics, it can be seen that there are a
number of ways that both bacterial and yeast probiotics could be of benefit in the
prevention and treatment of CDAD. A large number of clinical trials and case studies
have used different probiotic species, at varying doses and for differing lengths of
time to assess their impact on the disease.
1.26.1 Probiotics in primary prevention of CDAD
The proposal that probiotics could replace the missing elements of the normal GIT in
the prevention of CDAD has been investigated for nearly twenty years. There is
relatively little evidence for a preventative role because of a lack of published data.
The necessity to have large exclusion criteria, difficulty in recruiting adequate patient
numbers to provide definitive evidence are the main issues in prevention studies
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(Imhoff & Karpa, 2009). Of the studies that have been published, many have had too
few participants to show statistical significance between groups while many others
have been poorly designed.
One study investigated the ability of 2 x 1010 CFU per day of Lactobacillus
acidophillus and bifidobacterium to prevent CDAD. Of the 138 patients recruited,
2.95% of the probiotic group were C. difficile positive compared to 7.25% of the
placebo group. Even though the results look favorable, the study was inadequately
powered to show statistically significant differences between the two groups.
Another flaw identified in the study was that it may not have captured a true at risk
patient group as patients requiring more than 20 days of antibiotic therapy were
withdrawn from the study after day 20. It has been established that longer duration
of antibiotic use is associated with greater risk of CDAD; therefore, in this study
patients who developed CDAD past the 20 day period in both the treatment and
control group were missed (Plummer et al., 2004). Another observational analysis
did suggest a benefit from a combination of lactobacilli/bifidobacteria in CDAD
prevention.

There was an estimated reduction in CDAD of 66%. There were

limitations to the study results, as the data were gathered retrospectively and no
placebo group was included in the study design. The fact that historical controls
were used for comparison and that antibiotic usage and C. difficile strains may have
changed over time, meant the groups could not be regarded as truly comparable
(Graul et al., 2009).
1.26.2 Probiotics in the prevention of antibiotic-associated diarrhoea (AAD) as
a primary outcome, with CDAD as a secondary outcome
Several studies have investigated the capability of probiotics and yeasts to prevent
antibiotic-associated diarrhoea (AAD) and, as a secondary outcome, have assessed
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their effectiveness in the prevention of CDAD. The studies by Arvola et al., (1999),
Thomas et al., (2001) and Plummer et al., (2004) had insufficient numbers to truly
identify the benefits of probiotics in preventing CDAD. The yeast S. boulardii has
been studied in four clinical trials for the prevention of AAD with positive outcomes
(Surawicz et al., 1989a; Mc Farland et al.,1994; Kotowska et al., 2005; Can et al.,
2006). The dose of S. boulardii used in these studies ranged from 500 mg to 1 g
daily during antibiotic therapy or continued for up to two weeks after antibiotic
therapy. When these studies were analysed to assess the role of S. boulardii in the
prevention of CDAD as a secondary outcome, statistical significance was not
achieved. In three of the studies, a trend towards significance was reported (Surawicz
et al., 1989a; McFarland et al., 1994; Kotowska et al., 2005).
One randomized double-blind placebo-controlled trial did demonstrate a positive
outcome from probiotics administered in the yogurt drink, Actimel™. Actimel™,
contains a unique Lactobacillus casei strain, Lactobacillus casei imunitass, and two
yoghurt associated bacteria Streptococcus thermophilus and Lactobacillus bulgarius.
The drink was taken twice daily during antibiotic therapy and continued for one
week after antibiotic therapy was discontinued. The subjects were over 50 years of
age and were receiving either oral or intravenous antibiotics. A significant reduction
in the incidence of AAD was observed in the probiotic group (p=0.007) and there
was a significant reduction in the incidence of CDAD (p=0.001). No patient in the
probiotic group and nine patients in the control group developed CDAD.

The

absolute risk reduction ratio was 17% (Hickson et al., 2007). Since publication of
this study, it has been criticised. Wilcox & Sandoe (2007) state, that many patients
were excluded if they were “too high risk” and had more than two recent courses of
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antibiotics.

Overall, only 7% of the patients screened were deemed eligible to

participate in the trial. The control group received milk products which may have led
to more episodes of diarrhoea as the lactose contained in the product could have
triggered secondary lactose intolerance. Healthcare staff were not sufficiently
blinded to treatment allocation as products were in different containers. It is also not
clear that both groups were equally tested for C. difficile toxins when diarrhoea
occurred. Another issue that has been raised is that Streptococcus thermophilus and
Lactobacillus bulgarius are essential to the yogurt making processes and their
sensitivity to bile makes survival and colonic colonization unlikely. Despite the
initial promising results portrayed by this study, it does not appear to have the
strength it was first thought to have.
1.26.3 Probiotics in prevention of recurrence of CDAD
There are some case reports and clinical trials investigating Lactobacillus and S.
boulardii in the prevention of recurrent episodes of CDAD. Gorbach, in 1987,
reported the use of L. rhamnosus GG (1010 CFU) administered to five patients.
These patients had suffered two to five relapses of CDAD over a two to five month
period, despite antibiotic treatment. The treatment period with L. rhamnosus GG
was seven to ten days. Of the patients treated, four had no further relapses and one
patient improved initially but required a further dose of metronidazole. In another
study, L. rhamnosus GG (5 x 109) at a dose of 125 mg was given twice daily for two
weeks to four children, who had experienced three to five relapses of CDAD. All
four children had a reduction in stool frequency. However, two children suffered
relapses one to two months later requiring additional treatment (Biller et al., 1995).
Even though these are positive findings, limitations are inherent in these studies as
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with all case reports and, caution should be exercised before drawing definitive
conclusions.
Following the positive results from the case reports, two double-blinded,
randomized, placebo-controlled trials were conducted using the Lactobacillus
species. Wullt et al., (2003b) investigated the use of Lactobacillus plantarum 299v (5
x 1010 CFU/day) in patients who had one previous episode of CDAD in the previous
two months. Patients were randomized to receive 400 mg of metronidazole orally
three times daily for ten days and a fruit drink containing either the probiotic or
placebo. Eleven of the twelve from the treatment group and all those in the placebo
group achieved a clinical cure by days eleven to thirteen. In the follow up period,
four of eleven patients (36.4%) who received the probiotics and six of nine patients
(66.7%) in the placebo group experienced recurrence of CDAD symptoms; however,
this result was not significant due to the study being inadequately powered. A
further study by Lawrence et al., (2005) investigated the role of L. rhamnosus GG in
the prevention of recurrence of CDAD.

Adults with recurrent CDAD were

randomized to receive either 320 mg of inulin and L. rhamnosus GG (2.8 x 10

11

CFU) or a placebo or 360 mg of inulin orally twice daily while on antibiotic therapy.
The supplement was continued for an additional 21 days after the antibiotic therapy
was concluded. In three of the eight lactobacillus patients, and one of the seven
control patients, recurrence occurred. The C. difficile therapy also differed between
the groups and additional systemic antibiotics and gastric suppressive therapies were
used in individual subjects. The prebiotic, inulin, was used in both groups and may
have prevented differences being observed between the groups (Imhoff & Karpa,
2009). Although these two studies were randomized and placebo-controlled, they
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did not show positive outcomes for probiotics, perhaps due to the number of
limitations previously described.
S. boulardii has been shown to have a more influential role in managing CDAD
recurrence and there are some case reports and two positive double blind randomised
control trials (RCT) using this yeast.

In an open trial, there was successful

eradication of CDAD in eleven of thirteen patients when S. boulardii was
administered in combination with vancomycin (Surawicz et al., 1989a). Kimmey et
al., (1990) reported on the case of 6 patients with recurrent CDAD; S. boulardii was
commenced in the patients prior to discontinuing vancomycin therapy and continued
for a further 3 months. There were no recurrences of diarrhoea or colitis while taking
S. boulardii and this continued for a following 18 months. Following from this, two
randomized double blind control trials were conducted. Mc Farland et al., (1994)
recruited 60 patients with recurrent CDAD.

S. boulardii was found to provide

significant benefits, with nine of twenty-six patients (34.6%) experiencing recurrence
in the probiotic group compared to twenty-two of thirty-four (64.7%) in the placebo
group (p=0.04), a reduction in occurance of 46.5%. There was a similar positive
result in the trial conducted by Surawicz et al., (2002) during an eight week study.
However, only when high dose vancomycin (high dose = 2 g vancomycin, low dose
= 500 mg vancomycin) was administered in conjunction with S. boulardii, did the
yeast significantly reduce the recurrence of CDAD. Three of the eighteen S.
boulardii patients (16.7%) experienced recurrence compared to seven of fourteen
(50%) of the patients receiving high dose vancomycin and placebo (p=0.05). In a 5month follow up period, of those who received the probiotic and high dose
vancomycin, none of the 16 followed up experienced recurrence, while 3/13 (23%)
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of those given the placebo and high dose vancomycin experienced recurrence. These
two studies do show positive results and promise for the role of S. boulardii in the
prevention of CDAD recurrence. However, in the literature a number of valid flaws
have been identified in these two studies and are discussed in a review paper by
Miller (2009). In the study by Mc Farland et al., (1994) the study design did not
control for the dose or the duration of antibiotic. There was no benefit of the
probiotic in patients who had developed CDAD for the first time. The benefit
occurred only in the patients with recurrent CDAD. Furthermore, this study was
conducted before the NAP1/027/BI strain had been identified, so its potential benefit
on the current outbreaks of CDAD may not be as large. In the second study
conducted by Surawicz et al., (2000) the antibiotic therapy was not randomized in
the probiotic and placebo groups. The benefits were only seen in a sub-group of
patients in a study that already had a small number of patients. Safety concerns about
the use of S. boulardii in certain groups of patients are often quoted as reasons why
the routine use of this yeast in the prevention of CDAD recurrence is not yet fully
supported (Bauer et al., 2009).
1.26.4 Meta-analyses of probiotics and CDAD
The studies discussed previously have been included in a number of meta-analyses
examining the efficacy of probiotics in CDAD. Dendukuri et al., (2005) conducted a
systematic review, four studies were included. The benefit of probiotic therapy seen
in two studies was restricted to subgroups characterized by severe CDAD and higher
doses of vancomycin (McFarland et al., 1994; Plummer et al., 2004). The authors
considered that the two other studies were methodologically flawed (Surawicz et al.,
2000; Wullt et al., 2003b). Of the studies conducted in which the prevention of
CDAD was a secondary outcome, four studies were identified (Surawicz et al.,
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1989a; McFarland et al., 1995; Lewis et al., 1998; Thomas et al., 2001). These
studies had too few cases of CDAD and provided no evidence for probiotic
prophylaxis.

The conclusion from the review was that there was insufficient

evidence to support the use of probiotics in the prevention and treatment of CDAD
and further better designed and larger studies were required.
A meta analysis was conducted by Mc Farland (2006), again looking at the role of
probiotics for the prevention of AAD and the treatment of CDAD. The review
reported on the analysis of six RCT’s, the probiotics had a significant efficacy in the
treatment of CDAD (RR=0.59, 95% CI 0.41, 0.85 p=0.005). Only S. boulardii was
effective for treating CDAD. The author concluded that a number of different
probiotics strains showed promise as effective therapy for AAD and CDAD.
However, this analysis was criticized in letters to the editor by (Lewis, 2007) and
Dendurkuri (2007) who stated that both prevention and treatment studies were
combined, and the “pooled” odds ratio was driven by a single positive study.
Dendurkuri (2007) further commented that uncritical reading of Mc Farland’s metaanalysis was “misleading and risked the use of possibly ineffective, potentially
hazardous therapies”.
In 2008, a Cochrane review was conducted on the role of probiotics for the treatment
of C. difficile associated colitis. Only four studies met the inclusion criteria and the
data could not be pooled because of variations in patient recruitment, the types of
probiotics used, high dropout rates and variations in concommitant antibiotic
therapy. From the data analysed, the two conclusions reached were that firstly;
“probiotics are an unproven alternative or addition to antibiotics to cure infection
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with C. difficile” and “the studies used did not provide enough evidence to support
the use of probiotics for treating C. difficile infection” (Pillai & Nelson, 2008).
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1.27 Conclusion

CDAD is the most common cause of nosocomial infection, typically resulting in
symptoms of diarrhoea, abdominal cramps and fever, all of which compromise the
health of the vulnerable hospitalized patient. In recent years, with the emergence of
new virulent strains, the disease has become more severe and resistant to treatment.
Research into all aspects of the disease remains ongoing.
To have accurate information on the nutritional status of this patient group is
important. Although the prevalence of malnutrition in many disease states has been
well documented in the literature, yet there are little data available on the nutritional
status of patients with CDAD. Nonetheless, it is logical to assume that malnutrition
occurs frequently in this patient group, particularly when the risk factors of
prolonged hospital stay; ETF and increasing age are associated with both the
acquisition of CDAD and with the development of malnutrition. The aim of this
research was, therefore, to investigate the nutritional status of Irish patients who
develop CDAD and to compare these data with those of medical and surgical patients
within the same hospital and to published Irish data on the prevalence of
malnutrition.
The use of probiotics for the prevention and treatment of CDAD is relevant to the
professional practice of dietitians. To date, the scientific evidence for their efficacy
shows promise but conclusive evidence remains unavailable. Some studies surveyed
dietitians’ opinions and use of FF, however none have specifically looked at their use
of probiotics. With a large range of commercial products available and an emerging
body of research in probiotics, it is important to establish that the practices of
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dietitians are evidence-based, safe and consistent. This study will investigate Irish
dietitians’ opinions and recommendations for the use of probiotics in patients with
CDAD and other clinical conditions. Information about probiotic products being
recommended and used within Irish healthcare facilities and the factors that influence
probiotic selection will be obtained.
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CHAPTER 2 - Prevalence of malnutrition in patients who
develop CDAD
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2.1 Introduction
Clostridium difficile is the most common cause of diarrhoea resulting from
nosocomial infections (Johnson & Gerding, 1998).

There are a number of

identifiable risk factors for its acquisition; of these, advanced age and length of
hospital stay also predispose to malnutrition. It has been well established that the
presence of malnutrition is detrimental physiologically and clinically, impairing
quality of life and delaying recovery from illness (Stratton et al., 2003).

Data

suggest that disease-related malnutrition doubles the risk of mortality in hospital
patients and triples mortality in older patients (over 65 years) both in hospital and
following discharge (Stratton et al., 2006a; Stratton et al., 2006b). One UK study
reported that 57% of patients (n = 76) were malnourished at time of diagnosis of
CDAD (as per MUST classification) (Wong et al., 2008). Although it is generally
assumed that patients who develop CDAD are at increased risk of malnutrition, there
is little information in the literature to substantiate this. There are no data available
on the nutritional status of Irish patients who develop this condition and how this
compares to other patients admitted to hospital.
Nutritional screening is an assessment to identify those at risk of malnutrition and
who require further nutritional assessment. MUST has been developed to detect
protein-energy malnutrition and the risk of developing malnutrition using evidencebased criteria (Elia, 2003).

MUST takes into consideration three factors: BMI,

weight change and food intake and assigns equal weight to these three components,
as they have been shown to have statistically significant effects when considered
individually or together.

BMI indicates chronic protein-energy malnutrition;

however, this alone will not always detect patients at risk of malnutrition. Change in
weight reflects an acute change in protein energy status and unintentional weight loss
56

from outside the normal intra-individual range suggests the presence of underlying
disease processes or psychological problems that predispose to malnutrition. Recent
weight loss in ill patients is correlated with undernutrition-related complications and
these, in turn, are linked to poorer healthcare outcomes. Diminished food intake also
predicts deterioration in nutritional status.

2.2 Aims
The aim of this study was to assess the prevalence of malnutrition using the MUST
screening tool in patients at St Vincent’s University Hospital on diagnosis of C.
difficile associated disease (CDAD group) and to compare this to the prevalence of
malnutrition observed in a comparison group of patients in the same hospital.
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2.3 Methods and Materials
2.3.1 Study Design and setting
This was a prospective study in which all data were collected in a major academic
teaching hospital in Dublin, St Vincent’s University Hospital (SVUH). The hospital
has 479 inpatient beds and admits both medical and surgical patients.
Initially, the data collection for this study was one component of a collaborative
research project between the microbiology department of SVUH and the care of the
elderly department of the Mater Misericordiae Hospital, Dublin.

This research

project was titled “Immune Response and Molecular Epidemiology of Clostridium
difficile-associated Diarrhoea (CDAD)”: A Prospective Study. The collaborative
study set out to establish:
1. The epidemiology of prevalent C. difficile strains using molecular typing methods
and, from this information, the outcomes of infection and the rates of re-infection
versus relapse in recurrent CDAD;
2. The immune response to C. difficile surface layer proteins and their importance in
predicting recurrent diarrhoea and/or disease severity;
3. The genetic determinants of the innate and acquired immune response to C.
difficile.

Nutritional information (weight, height, BMI, Mini Nutritional Assessment
(Appendix 1)) and method of nutritional intake) was one aspect of the data collected
for the collaborative research project. These data were collected by the research
dietitian (YH) for 16 cases on the SUVH site. Data gathered for completion of the
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screening tool MUST (Appendix 2) were also collected. As the desired number of
patients for the collaborative research study had been achieved by March 2009,
further subject recruitment (n = 18) in SVUH continued independent of the
SVUH/Mater collaborative research project.
Data on the comparison group were gathered during a one day MUST compliance
audit that was conducted by the SVUH multidisciplinary Nutrition Committee in
November 2010. The data were collected by a multidisciplinary group that included
the research dietitian.

2.3.2 Ethical approval
Ethical approval to carry out this study was granted by the ethics committee of the
Dublin Institute of Technology [DIT reference 74/08] and the ethical and medical
research committee for St Vincent’s Healthcare Group. The audit committee of St
Vincent’s Healthcare Group and the SVUH Nutrition Committee granted permission
to use the data collected in the MUST compliance audit for the purpose of providing
a comparison group for this study.

2.3.3 Participants
Patients in the CDAD group were in-patients in SVUH who had a stool sample
positive for C. difficile toxin A or B. Initially, the subjects were identified by the
researchers working on the collaborative SVUH/Mater project. Once the subject had
given consent to participate, the dietitian was informed and the nutritional data were
collected. For the remaining subjects, the dietitian identified patients by regular
contact with the microbiology laboratory. Subjects were recruited between August
2008 and May 2010. Not all patients diagnosed with CDAD during this time were
recruited. This was due to re-submission to the ethics committee in SVUH for
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further permission for patient recruitment and also occasional difficulties in the
system of identifying patients with CDAD.
The comparison group patients were a group of patients from five wards (two
surgical and three medical) who were hospital inpatients on the audit date (total of 94
beds). The length of stay of these patients prior to audit varied. The data were
collected on the 24th November, 2010. Only patients for whom the date of admission
was available were included in the hospital comparison group (n = 59 patients were
audited on the day). Due to time limitations matching for the age and sex of the
comparison group to the CDAD was not possible. The other hospital patient group
was hoped to reflect a general hospital patient, with varying age, clinical conditions
and length of stay.
In the CDAD group 34 subjects were recruited and there were 36 subjects recruited
for the hospital comparison group.

2.3.4 Exclusion criteria
2.3.4.1 CDAD group
Patients were excluded if they were under 18 years of age or outpatients. Patients
were not included if they were already enrolled in another investigational study or
clinical trial and if, at time of diagnosis, were patients in ICU.
2.3.4.2 Hospital comparison group
Patients who were deemed too unwell or were not at their bedside at the time of audit
were excluded. Patient suitability was based on the discretion of those collecting the
data in consultation with ward nursing staff.
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2.3.5 Consent
2.3.5.1 CDAD group
In the CDAD patient group, a consent form was signed by both the participant and
the research dietitian and was filed in the patient’s medical notes (Appendix 3). In
cases where patients were unable to give written consent, the next of kin was
contacted and verbal consent was obtained and documented on the consent form and
filed in the medical notes.
2.3.5.2 Hospital comparison group
As agreed with the Audit and Nutrition Committees in SVUH, verbal consent for the
data collected for the MUST audit to be used as comparison group data for this study
was deemed sufficient. This was provided by all patients who participated in the
MUST audit.

2.3.6 Data collection
Detailed clinical data were obtained in the CDAD group within 72 hours of diagnosis
of CDAD. All data for the comparison group was collected on the 24 th of November
2010. For each case in both groups, baseline demographic details of age, gender and
date of admission were collected. Information was determined by patient interview,
medical chart review and review of nursing records. The data collection, patient
interview and anthropometric measurements were conducted by the research dietitian
for the CDAD group. For the comparison group, the data were collected by a
member of the multidisciplinary audit team that included the research dietitian.
Patients were allocated into diagnostic categories in accordance with BAPEN NSW
recommendations for diagnostic categories. The diagnostic categories are systems
based, and in patients with infection or cancer they are included within the relevant
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diagnostic category. The eight categories are central nervous system, gastrointestinal,
respiratory, cardiovascular, gentio/renal, musculoskeletal, others and not known.
Information was recorded on a standardised form for both groups (CDAD group,
Appendix 4; Hospital comparison group, Appendix 5). All patient identifiers were
removed and each patient was allocated a unique study number.
2.3.6.1 Nutritional Assessment
The main outcome measure of this study was the assessment of nutritional risk in
patients with CDAD. Although there is no universally accepted definition of
malnutrition nor is any one screening tool accepted as a gold standard, the MUST
screening tool was selected to determine nutritional risk in this study. This screening
tool is supported by the UK and Irish Departments of Health and expert bodies in
both countries (BAPEN, ISPEN, INDI, and Nutrition Society). Within the study
hospital itself, MUST has been shown to perform well against the previously used
screening tool and other commonly advocated tools (Keaskin et al., 2010). MUST
takes into consideration three independent criteria and has been shown to have
excellent agreement with a dietitian’s assessment of malnutrition. Additionally
advantages to its use include surrogate measures for current and previous weight and
height. This is particularly useful in patients with CDAD, as this group is older and
frequently frail or bedbound.
2.3.6.2 Anthropometry
The weighing of subjects was conducted where possible by the research dietitian or
member of the audit team. Weight was measured to the nearest 0.01 kilogramme
using ward scales (CDAD, n = 28; hospital comparison group, n = 32). Scales used
in SVUH are Seca 710 electronic column scales and Seca 955 electronic chair scales
62

(Seca Hamburg, Germany). All hospital scales are calibrated annually. In cases
where patients could not be measured accurately, recalled weight (if reliable and
realistic) was used (CDAD, n = 6; hospital comparison group, n = 4) (Elia 2003,
Stratton et al., 2003).
To obtain height in patients who were mobile and able to stand, height was measured
using a wall mounted stadiometer (Seca 220, Hamburg, Germany or Seca 222,
Hamburg, Germany) according to standard methodology (Elia, 2003) (CDAD, n = 2;
hospital comparison group, n = 9). The subject’s height was measured with the
patient standing straight and stretched, heels against the wall and the measurement
taken with the head in the Frankfort Plane position. In patients that were unable to
stand, ulna length (CDAD, n = 23; hospital comparison group, n = 18) was used to
calculate height. To calculate the patient’s ulna length, the patient’s arm (left) was
bent diagonally across the chest, with the palm is facing inwards and fingers pointing
towards the shoulders. The measurement is taken using a measuring tape (Seca 201,
Hamburg, Germany) between the central and most prominent parts on the styloid
process and the centre of the olecranon at the elbow. If ulna length was not able to
be conducted, recalled height was asked and used if deemed to be reliable and
realistic (CDAD, n = 9, hospital comparison group n = 9) (Elia, 2003; Stratton et al.,
2003).
2.3.6.3 MUST classification
For both patient groups, MUST was completed in accordance with the guidance
document (Elia, 2003). For step one, the weight and height obtained for the patient
was used to determine the patient’s BMI (weight (kg)/ height (m2)) and was scored
according to MUST classification. For step two of MUST, three methods were used
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to obtain the percentage of unplanned weight loss in the previous 3-6 months. Where
previous weights were documented in patients’ notes the difference from current to
previous weight was calculated (CDAD, n = 15; hospital comparison group, n = 8).
If a weight history was not documented, the patient was asked about their weight
history for the previous 3-6 months (CDAD, n = 15; hospital comparison group, n =
22). In subjects where reliable records or reports could not be obtained, subjective
criteria (the presence of loose fitting clothes or jewellery) was used (CDAD, n = 4;
hospital comparison group, n = 6). To determine a score for step three of MUST (the
acute disease affect on inability for nutritional intake for greater than 5 days) in both
patient groups, a combination of patient interview, review of the medical and nursing
notes and information from the nursing staff was used.
2.3.6. 4 MNA – CDAD group
For completion of the MNA screening tool the anthropometric details required for
current BMI (questions b) and weight loss (question f) were gathered in accordance
with the methods described above. Details required for the assessment questions on
current oral intake (question a), mobility (question c), psychological problems
(question d) and neuropsychological problems (question e) were obtained from
patient interview, nursing and medical notes and nursing staff.

2.3.7 Hygiene
All hygiene guidelines for dealing with patients and equipment were adhered to as
per HPSC C. difficile document (HPSC, 2008) (Appendix 6) and the SVUH infection
control manual (Appendix 7).
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2.3.8 Statistical analysis
Data from the standardised forms from both groups were entered and stored on a
Microsoft Excel (version 2007) database (Microsoft Corporation, Redmond,
Washington). For statistical analysis, a codebook was prepared. Each variable was
given a unique variable name and a numerical code was assigned to all applicable
variables (hospital comparison / CDAD group, gender and ward classification). The
data set was transferred to the Statistical Package for Social Sciences (SPSS) for
Windows Version 19 (IMB, SPSS Statistics, United States) for analysis. All data
were checked prior to analysis being performed. For categorical variables (sex,
CDAD/ hospital comparison group, ward and diagnostic criteria), frequencies were
analysed, maximum and minimum values were reviewed and it was established if
any cases were missing. For the continuous variables (age, length of stay (LOS),
MUST, BMI, weight and height), descriptive statistics were reviewed for out of
range values indicating incorrect figures or errors in the database. The characteristics
of both the CDAD and hospital comparison patient groups were described using
descriptive statistics. The normality of distribution of continuous variables in both
datasets was assessed using the result of the Kolmogorov-Smirnov test in
conjunction with an assessment of histograms, skewness and kurtosis values. As the
distribution of all continuous variables was skewed, the Mann-Whitney U-test was
used to test for differences in continuous variables (age, weight, LOS, MUST and
BMI) between the CDAD and comparison groups. Chi-squared (or Fishers Exact
Probability) tests were used to investigate differences between categorical variables
(sex, ward and diagnostic criteria) in both groups. Direct logistic regression was
performed to assess the impact of four variables (age, sex, BMI and MUST) on the
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likelihood of having CDAD. Statistical significance was set at a probability of less
than 5% (p < 0.05).
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2.4 Results
2.4.1 Subjects characteristics
All details for age, gender and date of admission were collected on 34 patients in the
CDAD group and 36 patients in the hospital comparison group. Of patients in the
CDAD group, 14.7 % (n = 5) were diagnosed with CDAD on admission to hospital,
the remaining patients in this group acquired C. difficile during their hospital
admission. Table 2.1 describes the patient characteristics. There was a statistical
difference in the age of the patients in each group (p = 0.002) with 85% (n =29) of
patients in the CDAD group aged sixty five years or older compared to 50% (n = 18)
in the hospital comparison group. There was no difference in LOS or primary
diagnosis between the two groups. There was a trend towards significance between
the groups in gender (p = 0.082) and if medical or surgical patients in the groups (p =
0.057).
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Table 2.1 Subject characteristics of CDAD and hospital comparison group
CDAD group

Hospital
Comparison
group

p value*

n = 34

n = 36

n (%)

n (%)

Female

24 (70.6)

17 (47.2)

Male

10 (29.4)

19 (52.8)

82 ( 72 -86.3)

64.5 (53.5 -77)

0.0022

Medical

21(61.8)

13 (36.1)

0.0571

Surgical

13 (38.2)

23 (63.9)

12.5 (3.8 -29.8)

15 (10 -28.5)

Central Nervous
System

1 (2.9)

4 (11.1)

Gastrointestinal
disease

9 (26.5)

11 (30.6)

Respiratory

4 (11.8)

3 (8.3)

Cardiovascular
disease

10 (29.4)

4 (11.1)

Genitourinary/renal

3 (8.8)

0 (0)

Musculoskeletal

3 (8.8)

8 (22.2)

Other

4 (11.8)

6 (16.7)

Gender
0.0821

Age (years)
Median (interquartile range)

Ward Location

Length of Stay (days)
Median (interquartile range)

0.3472

Primary Diagnosis:

0.1111

kg (kilogramme)
*p < 0.05 = statistically significant
1
Chi-squared test used to determine difference between groups; 2Mann-Whitney U test used to
determine difference between groups
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2.4.2 Risk of malnutrition
Malnutrition or risk of malnutrition was observed in 75.5% of the CDAD group and
66.7% of the hospital comparison group as classified by a MUST score of 1 or more.
This classification includes those at medium and high risk of malnutrition. There
was no statistical difference between the CDAD and hospital comparison group.
Table 2.2 describes the nutritional status of patients in each group. In the CDAD
group, underweight (BMI < 20 kg/m2) contributed to 38% of patients being classified
as “malnourished” (medium to high risk). In the hospital comparison group, only
22.2 % were underweight using BMI <20 kg/m2. Of patients in the CDAD group,
26.5% had a BMI less than 18.5 kg/m2 while in the comparison group, 13.9% had a
BMI less than 18.5 kg/m2. Although the MNA identified a greater number of CDAD
patients as malnourished or at risk of malnutrition (85.3% compared to 75.5%
identified using MUST), this was not statistically significant (p = 0.207). Table 2.3
describes a subgroup of those aged 65 years in the CDAD and hospital comparison
group. No significant difference between the weight, BMI and MUST scores in this
sub group.
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Table 2.2 Nutritional status of CDAD and hospital comparison group
CDAD group

Hospital Comparison

p value*

group
n = 34

n = 36

n (%)

n (%)

57.2 (47.3-68.0)

70.1 (56.9 -83.4)

0.0041

21.0 (18.2-25.1)

24.15 (20.5-29.6)

0.0151

<20

14 (41.2)

8 (22.2)

0.8111

20-24.9

11 (32.4)

11 (30.6)

0.8291

>25

9 (26.5)

17 (47.2)

0.1371

Score 0 = low risk

8 (23.5)

12 (33.3)

Score1 = medium risk

6 (16.7)

6 (16.7)

Score 2 = malnourished
or high risk

20 (58.8)

18 (50)

Weight (kg)
Median (inter quartile range)

BMI (kg/m2)
Median (inter quartile range)

MUST

MNA
Score 0-7
(malnourished)

18 (52.9)

Score 8-11 (at risk of
malnutrition )

11 (32.4)

Score 12-14 (normal
nutritional status)

5 (14.7)

*p < 0.05 = significant
1
Mann-Whitney U test used to determine difference between groups
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0.2671

Table 2.3 Nutritional status of CDAD and hospital comparison group of
subjects aged 65 years and older
CDAD group

Hospital Comparison

p value*

group
n = 29

n = 18

n (%)

n (%)

57.0 (47.1- 68.5)

58.8 (54.0 -74.1)

0.2601

21.2 (18.2-25.3)

22.2 (19.1-28.9)

0.3641

<20

12 (41.4)

5 (27.8)

0.9161

20-24.9

10 (34.5)

8 (44.4)

0.8941

>25

7 (24.1)

5 (27.8)

0.0601

0 (0)

0 (0)

Score1 = medium risk

7 (24.1)

5 (27.8)

Score 2 = malnourished
or high risk

22 (75.9)

13 (72.2)

Weight (kg)
Median (inter quartile range)

BMI (kg/m2)
Median (inter quartile range)

MUST
Score 0 = low risk

0.6811

*p < 0.05 = significant
1
Mann-Whitney U test used to determine difference between groups

2.4.3 Nutritional intake in CDAD group
Five patients were receiving ETF at the time of the study assessment. Two of these
patients were NPO and the remaining three were consuming some oral diet
supplemented with oral nutrition supplements (ONS).

All five patients were

receiving a polymeric enteral feed and only one patient was not being provided with
a source of fibre from the feed. Of those patients in the CDAD group, 47% were
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prescribed ONS in addition to their hospital diet. In each case, the ONS prescribed
were polymeric.
Two patients were prescribed a multivitamin and mineral supplement, and nine
patients were prescribed probiotics, the dose ranging from once per day to three
times per day. Either “probiotics” (n =3) or “Everybody” (n = 6) was written in the
medication kardex. There was no reference made to the probiotic strain.

2.4.4 Dietetic referral of CDAD patients
At the time of the study assessment, 55.5% (20 patients) with CDAD had been
referred to a dietitian. Of those referred, 65% (13 patients) had been prescribed
ONS. All five tube-fed patients had been referred; two were on nasogastric (NG)
feeds and three were on NG feeds to supplement their oral intake and had also been
prescribed ONS. 30 % (6 of the 20 patients) in the CDAD group that were classified
as high risk of malnutrition (i.e. with a MUST score of 2) had not been referred a
dietitian.

2.4.5 Direct logistic regression
Direct logistic regression was performed to assess the impact of a number of factors
on the likelihood of having CDAD. The model contained four variables (sex, age,
BMI and MUST), the full model containing all predictors was statistically significant
X2 (4 n = 70) = 15.11, p =0.04 indicating that the model was able to distinguish
between respondents who had CDAD and were the comparison group. The model as
a whole explained between 19.4% (Cox and Snell R square) and 25.9% (Nagelkerke
R squared) of the variance in CDAD status, and correctly classified 51.4% of cases.
As shown in table 2.4 only age made a unique statistical significant contribution to
the model (p = 0.043).
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Table 2.4 Direct logistic regression predicting likelihood of reporting CDAD
B

S.E.

Wald

Df

p

Odds
ratio

95.0 % C.I for
Odds Ration
Lower

Upper

Age

0.036

0.018

4.092

1

0.043

1.037

1.001

1.074

BMI

-0.095

0.063

2.285

1

0.131

0.909

0.803

1.029

MUST

0.062

0.205

0.092

1

0.762

1.064

0.712

1.590

Sex

-0.598

0.573

1.088

1

0.297

0.550

0.179

1.692

Constant -0.287

2.255

0.016

1

0.899

0.750

,
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2.5 Discussion
2.5.1 Nutritional status of CDAD group and hospital comparison groups
There was no statistical difference in MUST score between the CDAD group and the
hospital comparison group indicating that both groups were at equal nutritional risk.
However, a major limitation of this finding was that the groups were not matched for
age and sex. The CDAD group were older females on medical wards, whereas the
comparison group were younger and a greater percentage on surgical wards. Despite
these factors the findings of this study indicate that the CDAD group have a high rate
of malnutrition as defined by BMI. This is highlighted when compared to other data
on malnutrition in one other group of CDAD patients and published Irish data of
nutritional status in different hospital patient groups (table 2.5).
The high rate of malnutrition found in this CDAD patient group is supported when
compared to the UK study of Wong et al., (2008). A comparable percentage of
patients with CDAD in these studies were observed to be at risk of malnutrition. The
UK study reported that 57% of their CDAD patients were at risk of malnutrition, a
similar percentage to that observed in this Irish group of CDAD patients (58.8%).
Further comparison of these two groups of CDAD patients with the BAPEN data on
nutritional status of the general hospital population highlights that the prevalence of
nutritional risk is nearly double in CDAD patients. Using MUST to determine
malnutrition risk in the hospital setting, data from the 2010 NSW indicates that
malnutrition risk was identified in 33% of patients admitted to hospital most of
whom were at high risk of malnutrition (25%) with 8% at medium risk. Using these
data, the authors estimated a ward prevalence of malnutrition as 39% (assuming there
was no mortality and no “malnutrition” develops during the hospital stay) (Russell &
Elia, 2011). Previous data from an Irish setting found a prevalence of malnutrition in
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11% of medical and surgical patients on admission to two teaching hospitals (Corish
et al., 2000).

Both BMI and upper arm anthropometry were used to define

undernutrition.
The use is of the MNA again highlighted that CDAD patients are a group at high risk
of malnutrition as a similar number was classified at high risk by each screening tool.
The MNA identified more patients in the CDAD group as at risk of malnutrition
compared to MUST but this was difference was not statistically significant. There
were discrepancies between the two screening tools in patients identified as being at
risk; six patients classified as high risk using MUST were classified by the MNA as
only being “at risk” (n = 4) or “normal” (n =2). The MNA has been validated
specifically for the elderly (Guigoz et al., 1996) and it may not be valid to use with
these patients as both the CDAD and comparison patient groups included patients
under 65 years of age. The usefulness of the MNA as a malnutrition screening tool
in the acute setting could be questioned as it was originally validated for use in
relatively healthy older people (Rasmussen et al., 2004) and, therefore, it may not be
suitable for frailer older populations (Bauer et al., 2008b). Communication and
comprehension deficits in some older people limit its usefulness with such patient
groups and this factor was encountered in the study patient group. The MNA is
thought to be most effective for nutritionally screening those aged over 65 living in
the community, older residents in sub-acute care and those living in nursing homes
(Bauer et al., 2008b). Despite its limitations in using the MNA observed in this
study, the MNA is advocated as a nutritional screening tool particularly for use in the
elderly. In this study similar findings for nutritional risk were obtained using both
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methods. This supports the use of use of MUST as a screening tool able to identify
nutritional risk in this patient group.
Table 2.5 The nutritional status of the CDAD groups compared to other Irish
nutritional status data.
CDAD group

Wong et al.,
2008

Corish et al.,
2000

BAPEN

CDAD patients

Medical and
surgical
admissions

Nutrition
Screening Week
2010

34

76

569

1527

median

21.0

--

--

26.3

< 20 (%)

41.2

26

13.5

8

20-25 (%)

32.4

--

9

32

> 25 (%)

26.5

--

46

60

Score 0 (%)

23.5

--

--

67

Score 1 (%)

16.7

--

--

8

Score 2 or more
(%)

58.8

57

--

25

n

2011

BMI ( kg/m2)

MUST

-- data not provided/available

2.5.2 Nutritional status of patients 65 years and older in CDAD and
comparison groups
As the two study groups were not controlled the CDAD group were an older group of
hospitalised patients compared to the comparison group. It would be expected that
those with CDAD would be older as older age is considered a risk factor for the
acquisition of C. difficile.

This was also supported in the regression analysis
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performed on the data. The variable age, was found to be the statistically significant
variable in predicating the likelihood of having CDAD. In Ireland, the incidence of
CDAD increases with age with those aged over 65 years at highest risk of infection
(Health Protection Surveillance Centre, 2011). When those over 65 years of age in
both groups were compared there was no statistical difference seen between weight,
BMI and MUST score of these two groups. However, when the subjects over 65
years in the CDAD group are compared to Irish data of elderly populations, the high
nutritional risk of the CDAD group is evident. True comparisons are very difficult to
make as the patient groups were free living individuals, yet the vast contrast in BMI
emphasises that those with CDAD are a very malnourished group. One Irish study
reported that only 3% of healthy older people had a BMI lower than 20 kg/m2
(Corish & Kennedy, 2003). More recent data on the Irish free-living population
found that 1% of men and 2% of women over 65 years had a BMI less than 20 kg/m2
(Morgan et al., 2008). In those aged between 18-64 years, only 0.3% of men and 1%
of women had a BMI less than 18.5 kg/m2 ; the mean BMI for men over 65 years was
28.1 kg/m2 and women over 65 years was 27.3 kg/m2 (Irish University Nutrition
Alliance, 2011). The Irish Longitudinal Study on Aging (TILDA) published results
of a national study of 8000 older people aged 50 years and older in May 2011. Three
quarters of the subjects were overweight (44%) or obese (34%), only 1% of the
population were underweight (BMI < 18.5 kg/m2) (Barrett et al., 2011).

2.5.3 BMI
BMI is frequently quoted as an indicator of nutritional status and reflects chronic
protein energy malnutrition.

MUST and the Malnutrition Advisory Group of

BAPEN use the lower boundary BMI value of 20 kg/m2 to indicate the clinical risk
of underweight; the risk becomes even greater below a BMI of 18.5 kg/m2. These
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cut-off values are based on physiological and clinical observations which show loss
of body function as BMI decreases and the apparent normal body function in many
older subjects with a BMI above 20 kg/m2. RCTs of nutritional supplementation
suggest benefits are more likely in older subjects with a BMI below 20 kg/m2 with
less benefit seen in those with a BMI over 20 kg/m2 (Stratton et al., 2003). There is
some debate over the appropriate level of BMI to define undernutrition, for example,
WHO classifies normal or ideal BMI as 18.5 – 24.9 kg/m2 (WHO, 1998) while
BAPEN and the NICE guidelines consider that a BMI of between 18.5 and 20 kg/m2
indicates possible risk of protein-energy malnutrition. If a BMI of <20 kg/m2 was
used as the sole determinant of malnutrition, a prevalence of malnutrition of 41.2 %
in the CDAD group compared to 22.2% in the hospital comparison group would be
observed. The rate of 41.2% is high when compared to other Irish data on the BMI
of Irish hospitalised patients that was previously reported in a study carried out in
two Dublin hospitals. This study found only 13.5% of a mixed group of medical and
surgical patients had a BMI below 20 kg/m2 (Corish et al., 2000) (Table 2.5). A true
comparison is difficult, as the data in the older study was taken within 48 hours of
the patient’s admission to hospital, whereas in this study population, the data were
collected at various stages during hospital admission. In addition the percentage of
patients with BMI <20 kg/m2 in the study CDAD group is higher than the 26% with
a BMI <20 kg/m2 reported in the study by Wong et al., (2008). The high percentage
of patients with low BMI’s perhaps indicates that the presence of chronic
malnutrition is more common in patients with CDAD.
The differences observed in the BMI between the CDAD and comparison group
could question the use of the MUST as the indicator of nutritional risk in this patient
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group. There are a number of limitation of MUST, firstly MUST allows for the use
of surrogate and self-reported measurements for weight, weight loss and height. The
reliability and accuracy of these measurements can be questioned at the individual
level and in some cases are relying on subjective criteria. In the elderly population in
the presence of cognitive impairment it can be difficult and unreliable. In the CDAD
patient group the majority of the data for recent weight loss was based on selfreported or estimated data rather than accurate measurements which could impact on
the reliability of this information. In addition MUST assign equal weight to these
three components of the tool (BMI, weight loss and oral intake). It could be
questioned does a low BMI indicating chronic protein-energy malnutrition have a
greater impact on outcome compared to recent weight loss or short term reduced oral
intake in the CDAD patient group. However, it has been found BMI alone will not
always detect patients at risk of malnutrition. As MUST take into consideration a
BMI less than 20 kg/m2 it will captured that chronically malnourished group as being
at nutritional risk. As the majority of CDAD patients are the older population the
surrogate measures for weight and height are often the only way to obtain data due to
issues with mobility. In the CDAD patients there are a number of limitations when
interpreting BMI. CDAD can result in manifestations of protein losing enteropathy
involving ascites and peripheral oedema (Dansinger et al., 1996). Alterations in fluid
balance, such as the presence of oedema, can make it difficult to accurately quantify
the amount of excess extracellular fluid present. Although there are guidelines
available to estimate body weight for the presence of excess fluid (Wicks & Madden,
1994) these only provide and approximation of oedema free body weight and lack
precision. Future studies should consider if a low BMI is associated with in increased
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risk of C. difficile acquisition and disease outcome. It would be useful measurement
for the HPSC to collect in their surveillance data.

2.5.4 Identification of malnutrition in the patients with CDAD
The failure of nursing and medical staff to identify some patients in the CDAD group
who were at nutritional risk highlights the concern that malnutrition is frequently not
identified in healthcare facilities. This ongoing problem has been highlighted in the
declaration released at the 2011 international conference “Fight Againist
Malnutrition – Two Decades On”.

One of the four aims of the conference

declaration is to improve the identification of malnutrition.

The declaration is

endorsed by the EU, Polish Society for Enteral and Parenteral Nutrition, ESPEN,
European Nutrition for Health Alliance and the medical nutrition industry. The wide
support for this declaration indicates that malnutrition and its identification is a major
problem. In SVUH, there is a mandatory requirement to carry out MUST nutritional
screening on each patient admitted. However, compliance with this requirement
remains an issue. A hospital audit was carried out on 63 patient records on one day
in February, March and April 2011. Completion of the screening tool ranged from
44-59% over the three day audit resulting in a number of medium and high risk
patients who had not been identified on admission (Nutrition Committee SUVH,
2011). Despite the well-known medical and economic impact of malnutrition, it still
remains unidentified in hospitalised patients. Previous Irish data showed that 40% of
malnourished patients were referred for nutritional intervention (Corish et al., 2000).
Another study reported that of 40% patients at nutritional risk, only a small number
had been identified and no nutritional plan or monitoring systems were in place
(Rasmussen et al., 2004). More recently, the presence of nutrition problems were
observed in up to half the patients studied but these were only partly documented by
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health care professionals. Clinical judgement was used to identify malnutrition in the
majority of patients, BMI was not calculated and nutritional problems were not
documented in many cases (Volkert et al., 2010). The previously discussed NSW
2010 data also highlights the difficulty that remains with nutritional screening and
identification of malnutrition in Irish healthcare facilities. 72% of the hospitals did
not have a nutritional screening policy and only 38% of the hospital audited
nutritional screening (Russell & Elia, 2011). From the perspective of the study
hospital the documented failure to identify high risk patients highlights the
importance of the nutritional screening all patients. A comprehensive nutrition
screening protocol will detect all patients at high nutritional risk and if implemented
would have detected the six patients. Within any care setting there will always be
groups of patients who are at greater nutritional risk than others. A universal policy
of nutritional screening allows for all such patients to be detected and not only those
thought to be “at risk”. The finding that nutritional supplements were being
prescribed to patients that were not under the care of the dietetic service would
warrant further investigation at a hospital level. The introduction of education about
nutritional supplements to the relevant health care staff would be advisable to ensure
appropriate supplements are being prescribed. Another option that may be the use of
particular nutritional supplements being incorporated into care plans related to the
nutritional screening tool.

2.5.5 Provision of probiotics to the CDAD group
Although this study had only a small patient sample, it does highlight that probiotics
are being used in this patient group. However, the use of probiotics in patients with
CDAD in SVUH was inconsistent in this study.

Only 25% were prescribed

probiotics and, among these, the dose of probiotics varied.
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No hospital-wide

guidance on the use of probiotics in CDAD or other conditions exists in SVUH. In
addition the probiotic product supplied to patients contained L. rhamnosus GG for
which there is no conclusive evidence to support its use as an adjunct to antibiotic
therapy (Hickson, 2011).

2.5.6 Enteral nutrition and CDAD
In this study, only a small number of patients with CDAD were on ETF at the time
they became infected with CDAD. It should be noted that the total sample size was
small and that no patient had a gastrostomy in situ.

It has previously been

demonstrated that ETF is an independent risk factor for C. difficile colonisation
(Simor et al., 1993). Additionally post pyloric tube feeding significantly increases
the risk for the development of CDAD in hospitalized patients (Bliss et al., 1998).
One study in a Dublin teaching hospital followed 73 subjects who developed CDAD
through their hospital admission. Of these, 4.1% of patients were on PN and 30.1%
were receiving nutrition via a NGT or PEG. NGT insertion/feeding were associated
with more severe disease. However, this association was not statistically significant
(Kyne et al., 1999).

2.5.7 Future considerations for patients with CDAD
The purpose of this study design was to assess the nutritional risk as the time of
CDAD diagnosis. From extrapolation of the literature describing the effects of
infection it is commonly believed that CDAD is both a cause and effect of
malnutrition. However no literature specific to CDAD is available to support this
hypothesis. As this was an observational study whose primary outcome was the
MUST score of patients only limited data on the other factors associated with CDAD
development were collected. Accurate testing of the hypothesis that malnutrition
contributed to the likelihood of CDAD acquisition was not the primary outcome of
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the study and cannot be determined retrospectively as it would require the
availability of data on all possible contributors to malnutrition before a causal
relationship could be determined. Future work should look at above hypothesis as
well as the impact of CDAD on a patient’s nutritional status.
It is well established that nutritional status declines during hospital admission
(Braunschweig et al., 2000; Corish et al., 2000; Rasmussen et al., 2004). The Dublin
study of 73 subjects who developed CDAD during their hospital admission
mentioned previously classified 12.3% of their subjects as malnourished, defining
malnutrition as weight loss of greater than 10% of body weight. However, no
anthropometric data were provided at initial diagnosis of the disease (Kyne et al.,
1999).

Another significant factor for malnutrition risk in this patient group is

diarrhoea. Diarrhoea is most commonly defined as a minimum of three liquid stools
per day (WHO, 2005). It is characterized as a symptom of a disease in which the
large or small intestine becomes irritated and this results in rapid movement of faecal
matter through the large intestine. Diarrhoea leads to poor absorption of nutrients
due to the rapid transit in the gut, deterioration of the absorptive mucosa and loss of
specific transporters.

It may produce a secretory state in the small intestine,

preventing or reducing net absorption.

Many studies have shown that there is

evidence of carbohydrate malabsorption with diarrhoea with several focussing on the
disaccharide lactose as the enzyme lactase, responsible for lactose digestion, can be
reduced in enteric infection (Duggan & Nurko, 1997). Undigested carbohydrate may
draw fluid from the intestinal lumen due to osmosis (Duggan & Nurko, 1997). Fat
malabsorption may increase severity of the diarrhoea due to fatty acid induced
colonic secretions (MacLean et al., 1978). A study of faecal output and nitrogen
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content over a 24-hour period in eleven patients with CDAD reported a mean faecal
nitrogen loss was 38 mg/kg/body weight/day. The authors recommended that faecal
nitrogen loss should be considered in nitrogen balance studies in these patients
(Tayek et al., 1987). Loss of nutrients may also increase during diarrhoeal disease of
bacterial origin. Cellular debris increases, intestinal flora proliferates and undigested
solids may adsorb minerals including zinc and reduce their bioavailability.
If diarrhoea is persistent (usually classified as lasting more than 14 days), this will
have severe medical and nutritional implications (WHO, 1988). A close association
between diarrhoea and malnutrition is documented in the literature (Checkley et al.,
2008) with general acceptance that poor nutritional status, as assessed by
anthropometric measurements, leads to greater risk of diarrhoea (Chowdhury et al.,
1990; Checkley et al., 2002) and that pre-existing malnutrition is associated with
increased severity of diarrhoeal disease.

If left untreated, diarrhoea-induced

malnutrition can increase morbidity.
A further aspect of the pathophysiology of malnutrition is the disease process itself.
In recent years, there is a greater understanding that a combination of under - or
overnutrition associated with acute or chronic inflammation from the disease state
leads to altered body function and will worsen nutritional status (Jensen et al., 2010).
The clinical manifestations of CDAD result in systemic symptoms such as fever,
anorexia, nausea and malaise. Leucocytosis, raised C-reactive protein and low
albumin levels are frequently seen. Infection impairs nutritional status and body
composition in a number of ways. Firstly, infection is characterised by anorexia and
can range from as little as 5% to almost complete loss of appetite (Yaqoob & Calder,
2003). This will promote loss of lean tissue if nutritional intake is inadequate.
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Infection is also associated with increased basal metabolic rate during fever. Each
one degree in body temperature is associated with a 13% increase in metabolic rate
which in turn increases energy requirements.

The infection itself can result in

nutrient loss and malabsorption. In CDAD, as previously discussed, the symptoms
of the disease can result in malabsorption and nutrient losses. A further consequence
of inflammation as a result of the disease is altered metabolism and redistribution of
nutrients.

This is a result of the production of proinflammatory cytokines and

immunoglobulins by leucocytes. The synthesis of these acute phase protein results in
the loss of amino acids from skeletal and muscle tissues (Yaqoob & Calder, 2003).
Each of these factors impact on a patient’s nutritional status, including those
identified as being at low nutritional risk at initial nutritional screening.

This

highlights the need for nutritional screening to be carried out at regular intervals.

2.5.8 Limitations
There are two main limitations of this study. Firstly is the small sample size so,
interpretation of the results must be with caution. An additional criticism which was
previously discussed was that the hospital comparison group was not matched to the
CDAD group. As the hospital comparison group patients selected in this study came
from patients on both medical and surgical wards who were at different time points
in their admission, it was anticipated that the patient group would reasonably
accurately reflect the nutritional status and malnutrition risk of the general hospital
patient. Many advantages and disadvantages of matching are quoted in the literature.
Matching controls for confounding variables can be relevant when there is a
substantial difference in the occurrence of possible confounders between cases and
controls. Matching can increase a study’s effectiveness by forcing case and controls
85

to have a similar distribution across confounding variables (Rose & van der Lann,
2009). However, matching may introduce bias, as when trying to match the cases
with controls, some of the cases may be excluded as they cannot be matched. This
will therefore create a sample of cases that is not a true representative of the study
population. The variables chosen to match are very important. If the controls are
matched to cases based on a variable that is not a true confounder, this can impact on
the study’s accuracy (Rose & van der Lann, 2009). However, the failure to control
for age and sex in this study may be the reason why no difference was seen between
the MUST score in the two groups. There was a trend towards more females and
more medical patients in the CDAD group.

2.6 Conclusion
Despite the lack of a significant difference in the prevalence of nutritional risk as
determined by MUST between patients with CDAD and the other hospital group, this
study highlights that those with CDAD are at high risk of malnutrition. The data also
indicate that these patients are older, female and have a lower BMI perhaps implying
that they are more likely to be chronically malnourished. Both the groups studied had
a similar prevalence of nutritional risk, however it is clear irrespective of the method
used to ascertain nutrition risk that those patients with CDAD are at higher risk of
malnutrition.
The study assessed malnutrition only at time of diagnosis and further study as to the
effect of the disease on the nutritional status of patients with CDAD is warranted.
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CHAPTER 3 - Dietitians’ opinions and use of probiotics in
CDAD and enteral feeding practices in CDAD
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3.1 Introduction

As CDAD is a disease associated with altered GIT microflora, the idea that
probiotics may play some role in preventing the development or recurrence of the
disease is very appealing. The mechanisms of action of probiotics imply that there
are a number of ways that both bacterial and yeast probiotics could be of benefit in
CDAD. Over the past few decades, a number of probiotics have been investigated
for their effectiveness in the primary prevention of CDAD, the prevention of AAD
and subsequent development of CDAD as a secondary outcome, and prevention of
recurrence of CDAD.

Unfortunately, the results of these studies remain

inconclusive.
Dietitians are one of the healthcare professionals involved in the care of patients with
CDAD in both hospital and community settings. As a result of increased availability,
consumer awareness and use of probiotic products, dietitans are often asked for
advice on these products. It is vital that dietitians understand fully the scientific basis
of FF claims, including probiotics, as they are the healthcare professional with
primary responsibility for nutrition education and medical nutrition therapy
(Anderson et al., 1998). Information on dietitians’ opinions about probiotics and the
recommendations they currently make on their use in dietetic professional practice
has not been previously reported. To gather this information, a questionnaire was
designed

to

assess

Irish

dietitians’

opinions

about

probiotics

and

the

recommendations they currently make on the use of these products in a number of
clinical conditions, but with a specific focus on CDAD.
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3.2 Aims
The aims of this study were to:


Investigate Irish dietitians’ beliefs and recommendations regarding probiotics
in patients with CDAD and other clinical conditions;



Obtain data on the probiotic products and strains currently in use in Irish
healthcare facilities and assess the factors determining use of these products
and if guidance on their use exists;



Assess the current enteral feeding practices of dietitians in patients with
CDAD.
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3.3 Methodology
3.3.1 Participants
A self-completed questionnaire was chosen as the most appropriate research tool to
facilitate access to dietitians working in a range of professional settings and varied
geographical locations within the Republic of Ireland (ROI). When this study was
undertaken, there were 550 members of the the Irish Nutrition and Dietetic Institute
(INDI) with ROI addresses; each was sent a postal questionnaire.
The study design and methodology was approved by the ethics committee of the
Dublin Institute of Technology (DIT).

Permission to access its members was

approved by the executive council of the Irish professional body for dietitians, the
INDI.

3.3.2 Study questionnaire
The study questionnaire consisted of five pages and included an introductory page
explaining the background and rationale to the research (Appendix 8).

The

questionnaire was divided into four sections and consisted of a combination of 26
closed and open questions. Advantages to closed questions are that they are specific,
provide the same frame of reference for all respondents and allow for quantative
analysis (Wall et al., 2002). Disadvantages to closed questions are they can limit the
depth of participant response and consequently data collection (Bowling, 2009).
Open questions are often difficult to define, neither being strictly qualitative nor
quantitative, but can capture and identify issues that were not taken into
consideration in the closed questions (O'Cathain & Thomas, 2004).
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3.3.2.1 Demographic and professional data
Data on gender, place of employment, size of dietetic department in place of work,
number of years qualified, work setting and patient specialty were collected.
3.3.2.2 Dietitians’ opinions
Participants were asked if they believed probiotics had a role in the prevention and
treatment of CDAD. They were also asked if they recommend probiotics in their
clinical practice. A list of six clinical areas in which some studies have shown
positive results for probiotic use was included in the questionnaire. Participants were
asked if they recommend probiotics in these conditions. The names of other clinical
conditions in which they recommend probiotics were requested.
3.3.2.3 Provision of probiotics in the clinical setting
This section of the study questionnaire asked if the healthcare facilities in which the
participating dietitians worked provided probiotics to patients/clients and, if so, were
policies or guidelines on the use of probiotics available for some or all conditions in
which they were used. Participants were also asked to identify the form, strain and
brand of probiotic used in the healthcare facility in which they worked, and what
factor(s) determine the probiotic(s) products used. Current practice in recommending
the use of probiotics in the prevention or treatment of CDAD was ascertained,
specifically dietitians’ recommendations for probiotic use in patients prescribed
antibiotics,

and

those

with

CDAD

or

non-CDAD

diarrhoea.

Dietetic

recommendations for vitamin and mineral supplementation in patients with CDAD
were also elicited.
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3.3.2.4 Enteral feeding, CDAD and probiotics
The fourth section requested information about dietitians’ practices using probiotics
in patients fed via enteral tubes and the enteral feeds most commonly recommended
for patients with CDAD.
3.3.2.5 Pilot questionnaire
The survey questionnaire was piloted among dietitians (n = 11) working in one
nutrition and dietetics department in an acute academic teaching hospital to ensure
that the questions asked could be clearly understood and that the directions for
answering the questions were unambiguous. Piloting of questionnaires ensures that
questions are worded clearly and they are appropriate for the target population (Wall
et al., 2002). Following the pilot study, changes were made to some of the questions.
The option of “do not know” as an answer in the questions about dietitians’ opinions
was included [questions: 2 (a) and 2 (b)]. The wording of the question was changed
to reflect that dietitians recommend probiotics rather than the dietitian administering
probiotics to patients [questions: 3 (l), 3 (m), 4 (a) and 4 (b)].

3.3.3 Data collection
In order to maximise the response rate to the postal questionnaire, the
recommendations in the systematic review on the topic by Edwards et al., (2009)
were followed. A stamped addressed envelope was included with each questionnaire
to make responding easier. A prize was offered to participants as an incentive to
respond. A further call for participation offering an online method of response was
also offered.
In order to identify the winner of the prize, the questionnaires were coded. These
identification codes were removed once the data were collected. A request for
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further participation in the study was made using the INDI newsletter. This offered
an opportunity to respond to the questionnaire online up to four weeks after the
initial closing date with the aim of increasing the response rate.

3.3.4 Statistical analysis
A codebook was prepared. Each question in the questionnaire was given a unique
variable name, and numbers were assigned to each of the possible responses to each
question. For the three open ended questions, the responses were reviewed and
common themes identified. Six themes were identified and assigned a numerical
code and a further numerical code was assigned to those responses that did not fall
into the six themes. A data file was created following the format of the codebook
using Microsoft Excel (version 2007) database (Microsoft Corporation, Redmond,
Washington). The data set was then transferred to the Statistical Package for Social
Sciences (SPSS) for Windows Version 19 (IMB, SPSS Statistics, United States) for
analysis. Prior to analysis being performed, the data were checked for errors. All the
variables in the data set were categorical variables and checked by reviewing the
descriptive statistics. The minimum, maximum, number of valid and missing cases
were reviewed to ensure that all values were within the possible values for that
variable (Pallant, 2007). Once the data file contained no errors, descriptive statistics
were used to describe the dataset. As all the variables were categorical, frequency of
occurrence was used to describe the study variables. In the analysis of the questions
regarding use of probiotics in practice, the responses from dietitians working in the
“other category” were excluded. Many of these were not working directly with
patients/clients and therefore probiotic use was not applicable. Chi- squared tests
were performed to investigate differences between the opinions and the practices of
dietitians who worked in the hospital setting compared to the community setting and
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for differences between more and less experienced dietitians. For comparison of the
use of probiotics among dietitians, dietitians who responded that the use of probiotics
was not applicable to their practice were excluded from analysis. Due to the small
number of dietitians with greater than 25 years or less than one year professional
experience, age was grouped into three categories (less than one year to five years
experience, five to fifteen years experience and greater than sixteen years
experience). In cases where the lowest frequency in a cell was less than five Fisher’s
Exact Probability Test was used instead. Statistical significance was set at a
probability of less than 5% (p < 0.05).
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3.4 Results
3.4.1 Response rate
There was a 40.9% (225/550) response rate to the questionnaire. All responses were
returned via the postal method, there were no responses via the additional online
method that had been offered. Eleven responses were excluded from statistical
analysis as they were returned by student or transition members of the INDI (n = 2),
retired or non-practicing members (n = 4), questionnaire was not applicable to
current work (n = 3) or contained incomplete information (n = 2). Therefore, of the
225 questionnaires returned, 214 were included in the analysis.

3.4.2 Participant characteristics
Forty-three hospitals were represented by the questionnaire responses.

These

included responses from 10 academic teaching hospitals and from hospitals within
each of the four Health Service Executive (HSE) areas. Responses were received
from six private hospitals and from one hospital in the United Kingdom (Appendix
9).
Each of the four HSE areas was represented by responses from the community
setting, with the largest response from the Dublin Mid-Leinster region. Of those
employed in the community, 75.6% (n = 31) worked in primary care, 22% (n = 9)
had a mixed case load and worked in both health promotion and primary care and
2.4% (n = 1) worked only in health promotion.
The employment in the ‘other’ category was private practice (n = 8), consultancy (n
= 1), industry (n = 2), charity (n = 1), education (n = 2), research (n = 1) and other
HSE organisations (n = 3).
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In each category, the majority (47.7%; n = 102) of dietitians had six to 15 years
experience and worked with adults (79.3%; n = 158). Many treated both medical and
surgical patients. There was a subgroup of hospital dietitians who identified part or
all of their case load as working in critical care (n = 18). The demographic and
professional characteristics of the respondents are described in Table 3.1.
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Table 3.1 Demographic and professional characteristics of dietitians (n =214)
n (%)
Gender
Female

212(99)

Male

2(1)

Place of employment
Hospital

155(72.4)

Community

41(19.2)

Other

18(8.4)

Years qualified as a dietitian
Less than 1 year

4(1.9)

1-5 years

67(31.3)

6 to 15 years

103(48.8)

16 -25 years

28(13.1)

Greater than 25 years

12(5.6)

Patients worked with
Adults

158(79.3)

Paediatrics

31(14.5)

Both adults and paediatrics

23(10.7)

Not applicable

2(0.9)
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3.4.3 Dietitians’ opinions about probiotics in the prevention and
treatment of CDAD
There was no consensus among dietitians about the role of probiotics in both the
treatment and prevention of CDAD (Table 3.2). More than half (52.8%) responded
that they did not know if there was a role for probiotics in the prevention of CDAD
whereas almost two-thirds believed that they could play a role in the treatment of
CDAD (Table 3.2). There was no significant difference in the opinions of dietitians
working in community and hospital settings on the role of probiotics in the
prevention (p = 0.285) or treatment of CDAD (p = 0.680). There was also no
relationship between dietitians’ opinions about probiotics in the prevention (p =
0.119) or treatment of CDAD (p = 0.107) and the number of years qualified.
Additional comments were made by respondents about the role of probiotics in the
prevention of CDAD (n = 116) and their role in the treatment of CDAD (n = 124).
In the prevention of CDAD, a similar proportion commented on the positive
scientific evidence (19.8%; 23/116) as those who thought the scientific evidence was
lacking or inconclusive (18.1%; 21/116). One individual had positive experiences
with probiotics in preventing CDAD; however; 20.3% (24/116) commented on their
lack of experience or knowledge in the area. Of those who supported the use of
probiotics in the prevention of CDAD, the proposed mechanisms of action of
probiotics were mentioned by 29.3% (34/116).
Similar themes emerged in response to the use of probiotics for the treatment of
CDAD. The positive evidence for a role for probiotics in treatment was mentioned
by 29% (36/124) and the mechanism of action of probiotics in the treatment of
CDAD by 29% (36/124). For those who did not know or who did not believe that
probiotics had a role in the treatment of CDAD, the negative scientific evidence
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(30/124) or their own lack of experience (12/124) was quoted. More dietitians
reported positive personal experience in the use of probiotics in the treatment of
CDAD (5/124). A small number of respondents commented that a number of other
factors (5/124) such as the medical team or the patients influenced the use of
probiotics.
Table 3.2 Dietitians’ opinions on the role of probiotics in the prevention and
treatment of CDAD (n = 214)
Dietitians’ response

Role of probiotics in
the prevention of
CDAD

Role of probiotics in
the treatment of
CDAD

(%)

(%)

Believe probiotics have a role

33.6

65.4

Do not believe probiotics have a
role

13.6

3.7

Do not know if probiotics have a
role

52.8

30.9

Not applicable to dietetic practice

10.7

10.7

3.4.4 Recommendations for probiotics in the prevention and treatment of
CDAD
Most (65%) dietitians do not use probiotics for the prevention of CDAD although
almost two-thirds use them for the treatment of CDAD. Practice among those using
probiotics for the treatment of CDAD varies (Table 3.3). There was no statistical
difference between years qualified and use of probiotics in the prevention of CDAD
(p = 0.285) or treatment of CDAD (p = 0.73).

There was also no statistical

difference between dietitians working in community or hospital settings in their use
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of probiotics for the prevention of CDAD (p = 0.581) and their use of probiotics for
the treatment of CDAD (p = 0.45).
Table 3.3 Dietitians’ use of probiotics in the prevention and treatment of CDAD
(n = 196)
Dietitians’ response

Use of probiotics in the

Use of probiotics in the

prevention of CDAD

treatment of CDAD

(%)

(%)

Always use probiotics

9.8

36.4

Never use probiotics

65.0

27.6

Occasionally use

14.5

25.2

10.7

10.7

probiotics
Not applicable to practice

3.4.5 Dietitians’ recommendations for the use of probiotics in other
clinical conditions
Thirty-three (15.4%) respondents would never recommend probiotics in their clinical
practice. There was no association between those who recommend probiotics and
years qualified (p = 0.390). Of those who recommend probiotics (84.6%), this was
most frequently for the management of irritable bowel syndrome (IBS) (82.3%, n =
149). The use of probiotics in the other five clinical conditions that were provided as
options for the dietitians is illustrated in Figure 3.1. Respondents also provided other
conditions for which they would recommend probiotics. Antibiotic treatment and
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antibiotic-associated diarrhoea were

conditions

in which probiotics were

recommended most often. Dietitians also reported recommending probiotics for the
treatment of thrush, diarrhoea, diverticular disease, constipation, radiation enteritis,
cystic fibrosis, pouchitis, autism, sports nutrition, on an individual basis,
gastrointestinal distension, malnutrition and acute diarrhoea in children.

3.4.5.1 Probiotic use by dietitians with non-Clostridium difficile diarrhoea
There is variation in the use of probiotics in patients with diarrhoea that is not due to
C. difficile.

Forty two percent (n= 82) of dietitians working in hospital and

community settings stated that they would occasionally use probiotics when a patient
develops diarrhoea while on antibiotics in the absence of C. difficile toxins. When
diarrhoea occurs, C. difficile is not isolated and the patient is not on antibiotics,
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40.8% of dietitians would recommend the use of probiotics whereas 34.7% would
never recommend them in this situation.

3.4.6 Probiotic provision and guidance in healthcare facilities
3.4.6.1 Commencement of probiotics
In the hospital and community setting, respondents indentified “dietitians” as the
healthcare professional most likely to recommend the commencement of probiotics
in patients with CDAD. They also indicated that medical staff are the healthcare
professional group next most likely to recommend the administration of probiotics to
patients (Figure 3.2).
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3.4.6.2 Probiotic products supplied by healthcare facilities
To establish the probiotic products supplied by healthcare facilities, only the
responses from hospital dietitians were analysed (n = 155) as probiotics are not
supplied to patients within the community. Of the 43 hospitals, 93% (n = 40) buy
probiotic products for provision to patients.

Two hospitals no longer provide

probiotics for financial reasons and the dietitian in one hospital (maternity) reported
that probiotics are never used.
Eleven different products were reported as available for patients (Appendix 10).
There were some inconsistencies between dietitians working in individual hospitals
as to the products available.

Overall, it was evident that the yogurt drink

“Everybody” (Yoplait franchise produced by Glanbia plc Consumer Foods Division,
Dublin) was the most commonly available commercial product.

This product

contains the probiotic strain L. rhamnosus GG. The factors influencing the probiotic
supplied within hospitals were catering department choice (40.7%; n = 63) and
clinical evidence for the product supplied (16.8%; n = 26).

Twenty dietitians

(12.9%) reported that a combination of both factors mentioned above determined the
product supplied. Despite over half the dietitians surveyed reporting that clinical
evidence for the product influenced the product supplied, almost half (48.4%; n = 75)
did not know the strain present in the products used.
3.4.6.3 Guidelines /policies on the use of probiotics
To establish if there is guidance available to dietitians on their use of probiotics, the
study questionnaire investigated the existence of policies or guidelines in this area.
Responses from dietitians working in hospital and community settings only were
analysed (n = 196). Of these, 4.1% (n = 8) responded they had a policy or guideline
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in their place of work for the use of probiotics while 4.6 % (n = 9) responded they
had a policy or guideline in their place of work for the use of probiotics in CDAD.
The response to this question varied within individual hospital and community
settings, indicating that in those settings where a policy exists, not all staff were
aware of its existence. Among the additional comments provided by respondents (n
=55) at the end of the questionnaire, 21.8% (n =12) identified the need for policies or
guidance on probiotic use.

3.4.7 Enteral nutrition and CDAD
No standardardisation of practice was observed among dietitians in the use of
probiotics with enteral tube feeding (Figure 3.3).

Approximately one-third of

dietitians (30.6%) reported recommending the use of probiotics occasionally in
patients with CDAD who were being enterally fed and a similar proportion (36.2%)
recommended their use in other clinical conditions when enteral nutrition was
required. There was no statistical association between the place of work (p = 0.229)
or years practicing (p = 0.340) and the use of probiotics in ETF patients with CDAD.
Neither was an association seen between the use of probiotics in ETF in other
conditions and dietitians’ place of work or years of experience. The enteral feed
most commonly used in patients with CDAD by the majority of dietitians was a
polymeric feed (79.6%); few dietitians recommended the use of semi-elemental
(7.1%) or elemental (0.5%) feeds. There was no consensus on the provision of
dietary fibre to patients with CDAD; 31.6% provide no fibre to patients with CDAD,
27% use a mixture of a non-fibre containing feed with a fibre containing feed, while
only 17.9% stated that they would always recommend a fibre-containing feed.
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3.4.8 Vitamin and mineral supplementation and CDAD
The majority of dietitians (57.9%) reported recommending vitamin and mineral
supplementation during an episode of CDAD if warranted by the patient’s nutritional
status, while 17.3% consider both diagnosis and nutritional status when deciding
whether to recommend additional vitamin and minerals. Only one dietitian reported
routinely recommending a vitamin and mineral supplement in patients who develop
CDAD.
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3.5 Discussion
In recent years, there has been a greater awareness of the potential role of probiotics
with the emerging evidence of their efficacy in some human diseases, and the
increased availability of probiotic products to consumers.

Dietitians are key

healthcare professionals who can influence the use of probiotics both among
consumers and other healthcare professionals.

There are a number of studies

investigating dietitians’ attitudes towards FF (Lee et al., 2000; de Jong et al., 2004;
McConnon et al., 2004; Landstrom et al., 2007b). In the studies by Lee et al., (2000)
and Landstrom et al., (2007b) dietitians’ opinions of FF were investigated. The
authors did not differentiate between dietitians’ opinions about different FF. This is
the first study that has examined dietitians’ beliefs or attitudes towards probiotics
alone, specifically in relation to their professional practice. It also highlights some
aspects of dietetic professional practice currently taking place in the ROI.

3.5.1 Response rate
The response rate of 40.9% was lower than anticipated and has the potential to
introduce some bias to the results, as non-responders can undermine study validity
and thus generalisability to a wider population (Cook et al., 2009). A response rate
of 75% is considered ideal (Bowling, 2009); however; response rates to all types of
surveys have been declining (Bowling, 2005), especially among healthcare
professionals. This has been attributed to an increased demand to participate in
research activities (Cook et al., 2009). Cook et al., (2009) showed that the average
response rate to postal surveys among healthcare professionals was 56% (in studies
published from 1996-2005). Only 16% of the studies analysed achieved a response
rate of 75% or over. In the literature, response rates for postal surveys of dietitians
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have been between 46.8 and 53% (Cashman et al., 2003; Mackel et al., 2003; de
Jong et al., 2004). An online web survey conducted by another Irish dietitian on the
topic of professional development at the same time and to the same group of
dietitians had a similar response rate (43.7%) (Fitzpatrick, 2010).

3.5.2 Participants
The employment profile of the study participants was similar to that obtained from
the INDI workforce planning survey of clinical nutritionist/dietitians undertaken in
May 2010 (INDI, 2010). This showed that 72% of dietitians were employed in
public and private hospitals and 28% in the community setting. It is, possible that
dietitians with greater experience of managing CDAD were more likely to complete
the questionnaire. As 73% of CDAD cases in Ireland occur in hospitals (HPSC,
2010); this may have resulted in the higher response rate from dietitians working in
that setting.

Additionally, CDAD is more commonly seen in adults and older

persons which may account for the lower response from dietitians working in the
paediatric setting.

3.5.3 Dietitians’ use and opinions of probiotics and CDAD
There is no consensus among Irish dietitians on the role and use of probiotics in the
prevention and treatment of CDAD with more than half of all dietitians surveyed
(52.8%) reporting that they did not know if there is a role for probiotics in the
prevention of CDAD. There was greater support (65.4%) for a role for probiotics in
the treatment of CDAD. As might be expected, given the number of dietitians who
did not know if there was a role for probiotics in the prevention of CDAD, the
majority do not recommend probiotics for its prevention. In the treatment of CDAD,
no consensus on the practice of recommending probiotics was evident. Some
dietitians recommended probiotics occasionally, and some in all cases, to prevent
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and/or treat CDAD. This is despite the lack of published evidence to support the use
of probiotics in the treatment of CDAD. Although there appears to be a possible role
for use of the probiotic S. boulardii in conjunction with high dose vancomycin in the
prevention of CDAD recurrence (McFarland et al., 1994; Surawicz et al.,2000),
randomised double-blind placebo trials of sufficient size to detect significant
differences are still lacking. Currently, this yeast is not being used as a probiotic in
Irish hospitals.
The treatment guidance document for CDAD from the ESCMID (Bauer et al., 2009)
states that there is insufficient evidence to recommend probiotics in addition to
antibiotics for the treatment of CDAD. The guidelines make reference to safety
issues that have been reported with S. boulardii (Bassetti et al., 1998; Munoz et al.,
2005) and the increased mortality observed in a study when probiotics were used in a
RCT in patients with acute pancreatitis (Besselink et al., 2004). The UK guidelines
from the Health Protection Agency & Department of Health (2008) also comment on
the use of probiotics in CDAD. They currently do not recommend probiotics to
prevent CDAD due to the lack of statistical significance in two meta-analyses by
Dendukuri et al., (2005) and Pillai & Nelson (2008). US clinical practice guidelines
also do not recommend the administration of probiotics to prevent primary CDAD.
This is due to the lack of evidence and the potential risk of blood stream infection
from probiotic use (Cohen et al., 2010). There is also no support for the routine use
of probiotics from the Australasian Society for Infectious Diseases; again this is
based on the lack of efficacy and the potential for adverse events reported in the
scientific literature (Cheng et al., 2011).
Irish dietetic practice should follow the guidance provided by the review document
‘Surveillance, Diagnosis and Management of Clostridium difficile in Ireland (HPSC,
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2008). Following their review of the evidence on probiotics, the HPSC concluded
that the routine use of probiotics cannot be recommended. Probiotics should not be
used either in the prevention or treatment of CDAD until there is more conclusive
evidence for their use. Moreover, the specific probiotics currently used to prevent or
treat CDAD in Irish health care facilities have even less evidence for their use than
those referred to in the studies above.

3.5.4 Dietitians’ recommendations for probiotic use
Only 15.4% of dietitians never recommend the use of probiotics in their practice. In
those recommending probiotics, IBS was the most common condition for which they
were recommended (by 81.4%). These findings are comparable to those of US
gastroenterologists; the majority (98%) of gastroenterologists supported the use of
probiotics in patients with IBS (Williams et al., 2010). The symptoms of IBS are
thought to be due to bacterial overgrowth in the small intestine causing increased
fermentation and gas production (Wilhelm et al., 2008).

The most commonly

studied probiotics in IBS are Lactobacillus, Bifidobacterium and the mixture
probiotic product VSL#3 (Williams, 2010).

The NICE guidelines on the

management of IBS, published in 2008, reviewed thirteen studies that met their
inclusion criteria and concluded that probiotics are effective in some people with IBS
but not in all. When products were from reputable sources, no harm was identified
from the ingestion of probiotics.

The NICE guidelines conclude with the

recommendation that ‘people with IBS who choose to try probiotics should be
advised to take the product for at least four weeks while monitoring the effect.
Probiotics should be taken at the dose recommended by the manufacturer’ (NICE,
2008). A systematic review on the use of probiotics in IBS conducted by Moayyedi
et al., (2010) which included 18 papers with 1650 participants concluded that
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probiotics had a statistical effect in reducing IBS symptoms, but that there was no
difference in the different types of probiotics used, all of them showing a trend
towards benefit. The main limitation acknowledged in this review was the number
of different probiotic strains and doses used in the studies reviewed and therefore no
recommendation on the best probiotic and dose for the treatment of IBS were made.
This limitation has been reiterated by other authors investigating this topic
(Williams, 2010).
For more specific evidence and guidance for the dietetic profession, the British
Dietetic Association (BDA) gastroenterology specialist group developed UK
evidenced-based practice guidelines for the dietetic management of IBS in adults.
Their inclusion criteria were studies that used probiotic products that are available to
consumers in the UK. Of the five studies identified, the results were too weak to
support the therapeutic use of probiotics in IBS. They advised that interventions
using probiotics to further improve IBS symptoms can be considered within second
line dietary treatment. As with other reviews and guidelines, there was insufficient
evidence to recommend a specific probiotic.

The dietetic practice guideline

recommended that patients should be advised that some products in probiotics may
increase IBS symptoms, that the long term effects of probiotics are unknown and that
if there is no improvement with one probiotic product, another one may need to be
tried (Mc Kenzie et al., 2010). It would seem reasonable for Irish dietitians to
recommend probiotics for IBS patients in a manner similar to that of UK dietitians.
However, specific guidance on probiotic products available on the Irish market
would be useful for practicing dietitians.
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The lack of support for probiotics in the management of the paediatric condition,
necrotitsing enterocolitis (NEC), may be explained by the low response rate from
dietitians who work with children and, that even within paediatrics, the management
of NEC is a specialist area.

3.5.5 Use of probiotics in other clinical conditions
A number of other clinical conditions in which this group of dietitians would
recommend probiotics were cited.

Antibiotic treatment and antibiotic-associated

diarrhoea were the most common situations in which probiotics would be suggested
(by 12% and 8.7% of dietitians respectively).

In comparison

probiotics were

recommended by 21% Dutch dietitians, for those with recent diarrhoea and after
antibiotic treatment (de Jong et al., 2004). This study investigated FF in general
rather than probiotics specifically, and so contained limited detail on products used
and doses recommended. In a study of New Zealand GPs (n = 45), probiotics were
mostly commonly recommended for diarrhoea (44.4%) (Schultz et al., 2011).
However, there was no information given on the cause(s) of diarrhoea in this study.
AAD is a common problem, occurring in 5-25% of patients receiving antibiotics,
although the rates reported depend on the antibiotics used and the population studied
(Bartlett, 2002). Probiotics given in conjunction with antibiotics for the prevention of
AAD have been extensively studied in both children and adults. Several systematic
reviews document that most of the probiotics tested have been shown to be effective
in reducing risk of AAD in the general population (Cremonin et al., 2002; D’Souza
et al., 2002; Hawrelak et al., 2005; Szajewska & Mrukowicz, 2005). L. rhamnosus
GG and S.boulardii are documented as being most efficacious. These are the strains
which have been most commonly used in the studies. From a review of all studies, it
can be concluded that the results of studies using probiotics to reduce AAD are
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promising but that conclusive evidence is still lacking, additionally it cannot be
stated that all probiotic strains are effective (McFarland, 2009) Again the findings
from this study show that this group of dietitian are using probiotics in an area where
the evidence does not fully support their use.

3.5.6 Probiotics supplied in hospitals/ healthcare facilities and guidance
around probiotic use
From this questionnaire it is evident that probiotics are being provided to patients in
the majority of hospitals and other health care facilities in Ireland. The dietitians
have identified themselves as the primary healthcare professional to recommend
probiotics in CDAD. Similarly, in a randomly selected group of Canadian dietitians,
81% (n = 122) they too believed that dietitians were the most appropriate
professional to recommend FF (Sheeshka & Lacroix, 2008). Such beliefs mean that
dietitians should have a good knowledge of FF, the probiotic products provided in
healthcare facilities and also the evidence for their use. The dietitians surveyed in
this study had poor knowledge of the probiotic strains in the products they supplied
or recommended. Around half (47.7%) could not identify even one strain present in
the product supplied. The catering departments of healthcare facilities were also
reported to have the biggest influence on the probiotic supplied. One issue that is
very clear from the studies carried out with probiotics in the treatment of various
clinical conditions is that the positive effect is dose and strain dependent. The
administration of a probiotic product that may only contain one strain to a diverse
hospital population could be described as futile. The limited knowledge of dietitians
of the strains being used, despite them taking responsibility for recommending
probiotics, identifies a deficit in knowledge and professional practice.
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The presence of policies or guidelines on the administration of probiotics within
clinical settings appeared to be unclear, with disagreement within departments as to
the existence of guidelines. Analysis of the practices of dietitians working in specific
areas was not possible due to the mixed caseloads of many dietitians. However, a
sub-group of 18 (8.4%) dietitians working in critical care was apparent, although it
should be noted that some dietitians did not work solely in the ICU setting. ICU is
the one area where guidance exists for dietitians on the use of probiotics. The recent
Canadian Critical Care Guidelines (2009) state that there is insufficient data to make
a recommendation on the use of probiotics, prebiotics and synbiotics in the critically
ill (Heyland et al., 2009). The Committee considered that the studies available are
inconsistent in their method of reporting outcomes such as septic mortality,
complications and diarrhoea. The variability in the probiotics used in studies and the
choice of control group made the published studies difficult to assess. The probiotic
prophylaxis in predicted severe acute pancreatitis (PROPTRIA) trial (Besselink et
al., 2004) and concerns about risk associated with S. boulardii were also a cause for
concern for the Committee.

The American Society for Parenteral and Enteral

Nutrition (ASPEN) Critical Care Guidelines of 2009 reiterate that recommendations
cannot be made about the use of probiotics in the general ICU population, again due
to the lack of consistent outcomes (McClave et al., 2009).
The safety issues highlighted in the literature would appear to be an aspect needing
consideration. Although dietitians’ opinions about the safety of probiotics were not
specifically investigated in this study, some respondents highlighted that they would
not use them in specific patient groups (i.e. infants and immunocompromised, ICU
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and paediatric oncology patients). Safety concerns arising from the use of probiotics
were not apparent in the questionnaire responses.
The reasons quoted for not using probiotics by Dutch dietitians related to safety and
functionality of the products and to products containing bacteria or

“foreign”

invaders (de Jong et al., 2004). In another study, nutritionists (Mc Connon et al.,
2004) expressed concern about the risks associated with probiotics; however, this
study focused on FF as a group of foods and did not seek specific detail on dietitians’
opinions on the safety aspects of probiotics.

3.5.7 Type of enteral feed used in CDAD
Although the majority of dietitians used a polymeric feed, there was no consistent
practice in the provision of dietary fibre to patients with CDAD. A small number of
studies have investigated the impact of diet on the acquisition and growth of C.
difficile. The results of this study showed that few dietitians used elemental enteral
feeds in their clinical management of CDAD patients. Elemental diet is thought to
favour the growth and proliferation of C. difficile. An in-vitro culture study found
that elemental diet enhanced the number of C. difficile and induced the production of
C. difficile toxin (Iizuka et al., 2004). It has been reported that C. difficile toxin was
frequently detected in patients undergoing elemental diet therapy who were not
taking antibiotics. Faecal C. difficile toxin disappeared soon after the elemental diet
therapy stopped (Itou et al., 1999; Itou et al., 2000). Elemental diet contains no
complex carbohydrate; the absence of dietary fibre and resistant starch disturbs
microbial balance in the GIT and deprives the colonic epithelium of its chief energy
source and proliferation regulator. This reduces fermentation and the production of
short chain fatty acids (SCFA), especially the SCFA butyrate. It has been shown that
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butyrate deficiency in the colon potentiates the growth and toxin production of C.
difficile organism (May et al., 1994). It has also been suggested the relatively large
amounts of amino acids in elemental diet may to provide a favourable environment
for C. difficile. A recent review by O’Keefe (2010) stated that elemental feeding as a
risk factor for C. difficile infection is frequently overlooked.
To provide guidance for dietitians on the provision of fibre to this patient group, the
mechanisms of action of fibre in the GIT should firstly be examined. Studies that
investigate the impact of fibre on the management of diarrhoea should also be
reviewed, given that diarrhoea is the major symptom of CDAD.

Fibre intake

influences nutrient absorption, carbohydrate, fat and sterol metabolism, stool bulk
and weight, colonic fermentation and gastrointestinal transit time (Kapadia et al.,
1995; Alam et al., 1998). Fibre also improves gut barrier function, helping to
prevent translocation of bacteria and toxins from the gut into the systemic circulation
(Spaeth et al., 1995). Fibre also promotes increased turnover or regeneration of
epithelial cells (Rehman et al., 2003).
The effects of

supplementing enteral feeds with dietary fibre in both healthy

volunteers and patients in hospital and community settings was investigated in a
systematic review and meta-analysis of 51 studies (Elia et al., 2008). The authors
concluded that fibre supplementation was generally well tolerated. In the hospital
setting, incidence of diarrhoea was reduced as the result of fibre administration (OR
0.68; 95% CI 0.48-0.96). Results showed a strong effect of fibre in reducing the
incidence of diarrhoea in patient groups with a high incidence of diarrhoea and a
smaller or absent effect in those with a low incidence of diarrhoea.

A likely

mechanism underlying the effect of fibre in reducing diarrhoea is the stimulation of
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colonic water and electrolyte absorption by SCFA that are produced as a result of
anaerobic metabolism of fibre. SCFA have been shown to reverse fluid secretions in
the ascending colon during enteral feeding (Bowling et al., 1993). SCFA production
depends on the number of types of bacteria species present in the colon, substrate
source(s) and gut transit time (Wong et al., 2006) , all of which have a number of
properties that may be of benefit in maintaining normal bowel structure and function,
and preventing or alleviating colonic based diarrhoea. SCFAs and acidic pH have
been shown to contribute to resistance to C. difficile colonisation and proliferation in
vitro (Rolfe & Iaconis, 1983; Rolfe, 1984). Different types of dietary fibre affect the
type and amount of SCFA produced. Nakao et al., (2002) reported an increase in the
ratio of anaerobic bacteria to aerobic bacteria with fibre supplementation. This may
be beneficial as anaerobic bacteria are thought to protect against the overgrowth of
potential pathogens, some of which may cause diarrhoea (Bourlioux, 1997). It is
thought that lack of dietary fibre could produce an intestinal environment conducive
to the growth of C. difficile. The recent review by O’Keefe (2010), speculates that
the prolonged use of low fibre tube feeds will enhance C. difficile colonization and
subsequent C. difficile associated colitis by reducing the resistance to pathogen
adherence and subsequent cytotoxic injury.

3.5.8 The provision of probiotics via an enteral tube
A limitation of the present study was that the questions asked of dietitians about their
use of probiotics with enteral tube feeding did not distinguish between the positions
of the enteral tube. Such questions would have provided more detailed information
on dietetic practice.

It appears that approximately half of all dietitians either

regularly or occasionally recommend probiotics via enteral feeding tubes in both
CDAD and other clinical conditions. There is very little guidance from the scientific
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literature or the probiotic or enteral feeding tube industries in this area. Danone
Ireland Limited, the company that produce “Actimel” does not recommend the use of
probiotics via enteral feeding tubes; the reason provided by the company is that
clinical evidence is lacking to support its safety if used in this way, as the product is
intended for oral consumption and has only been tested for oral use (Cox, M. 2010
pers. comm., 15 May 2010). Communication with representatives from Yakult,
Ireland (Yakult) and Glanbia (“Everybody”) indicated that neither company had
guidelines for the administration of their products via enteral feeding tubes (Jordan,
D. 2011 pers. comm., 19 January; McGartland, C. 2011 pers. comm., 19 April;).
Three companies that manufacture enteral feeding tubes that are commonly used in
Irish healthcare facilities were contacted to seek their position on the administration
of probiotics via enteral feeding tubes. No company had recommendations; some of
their comments compared the administration of probiotics to the administration of
medications via enteral feeding tubes (Nolan, O. 2010, pers. comm., 4 May; Coakley,
D. 2010, pers. comm., 14 May; Smith, R. 2010, pers. comm., 14 May).
The safety issues that arise with probiotics and nutrition support were addressed in a
recent review by Whelan and Myers (2010). Patients receiving nutrition support are
often high risk patients who are frequently critically ill and at risk of bacterial
translocation or are immunocompromised and, so, have additional risk factors for
probiotic infection. They are, also, regularly on medications that increase gastric pH.
The method of administering nutrition support can increase patients’ risk; postpyloric feeding enteral nutrition by-passes the gastric acid barrier completely and this
can result in a greater innoculum of the probiotic surviving in the small intestine. A
10-fold increase in the dose reaching the small intestine has been reported (Whelan
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& Myers, 2010). Central venous catheters (CVC) are used in the administration of
parenteral nutrition (PN) and these have been identified as a potential risk factor for
probiotic infection (Boyle et al., 2006). The review by Whelan and Myers (2010)
included 20 case reports and 52 papers with 53 trials (41 RCT’s and 12 nonrandomized trials).

In the case reports examined, 32 patients received various

methods of nutrition support and probiotics of varying strains and doses.
Bacteraemia occurred in five cases and fungaemia in 27 cases. Two patients also
developed endocardititis (Land et al., 2005; Munoz et al., 2005). The risk factors
were variable, but the majority of patients who developed infections had received
antibiotics and had intravenous access. In eight patients, the adverse events resulted
in death. The cases in which infection developed had used L. rhamnosus GG or S.
boulardii. The authors commented this is probably due to these strains being used
more frequently rather than them having greater virulence. The presence of a CVC
also carried a greater risk; many of these patients were in ICU and required a CVC
for their medical management although it was highlighted that the CVC tips were not
examined for contamination. The authors of this review concluded that the risk of
environmental contamination may also occur and be a greater risk factor than
administration of probiotics. In the case reports of S. boulardii fungaemia, the
patients themselves were not receiving the yeast but patients located beside them
were (Cassone et al., 2003; Graf & Gavazzi, 2007).
In the 53 trials examined by Whelan and Myers (2010), the probiotics used varied
and were administered in varying doses and using a range of administration methods.
Subjects in the studies were from a variety of locations with a range of disorders.
Many of the studies showed a reduction in mortality, sepsis or infection; in general
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the studies showed either no effect or a positive effect of probiotic use on the overall
outcome. Only three studies, (one post liver transplant, another in acute pancreatitis
and a further study in NEC) found significant increases in negative clinical sequelae
which were largely non-infectious in nature (Besselink et al., 2004; Rayes et al.,
2005; Lin et al., 2008). In two of the RCT’s, there was increased negative outcome
in patients in which the probiotics were administered via naso jejunal tube (NJT)
(Besselink et al., 2004; Rayes et al., 2005). Whelan and Myers (2010) remark, in the
three trials with negative outcomes, there are some issues with the study designs.
One of the trials had low numbers which may result in statistical error (Rayes et al.,
2005) and in the second trial a novel probiotic was used and the study itself has been
heavily criticized (Besselink et al., 2004). In many of the studies the probiotic
strains were not characterized, inconsistent doses were reported, probiotic infection
occurred at different doses of probiotics, adverse events were either unreported or
there was a lack of information about the adverse events. In the cases where patients
died, it was difficult to attribute the patient’s death to probiotic infection.

3.5.9 CDAD and mineral and vitamin supplementation
The symptom of diarrhoea which can often be persistent and severe in CDAD can
impact on the individual’s nutritional status, especially micronutrient status. There is
no guidance in the literature on the provision of additional micronutrients during
CDAD. From the results of this study, it can be seen that a dietitian’s decision to
supplement with vitamins or minerals appears to be generally based on his/her
clinical judgement. A more structured approach should be considered as mineral
balance is always altered when diarrhoea persists for more than a few hours (Wiesen
et al., 2006). A range of micronutrient deficiencies during diarrhoeal disease has
been described; some of the micronutrient deficits identified are copper, iron,
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magnesium, selenium, zinc, folate and vitamins A, B12 and D (Tomkins et al., 1993).
Micronutrient deficiency impairs immune function and increases susceptibility to
infection (Yaqoob & Calder, 2003).
Zinc is a micronutrient that has been extensively studied for its role in diarrhoea. In
the GIT, it restores mucosal barrier integrity and enterocytes, promotes brush border
enzyme activity and the production of antibodies and circulating lymphocytes against
intestinal pathogens (Shankar & Prasad, 1998; Hess et al., 2009; Prasad, 2009). The
association between zinc and diarrhoeal associated morbidity was first noted in early
observational studies that documented increased faecal zinc loss, a negative zinc
balance and low tissues zinc concentration among children with diarrhoea (Anon,
Zinc and copper wastage during acute diarrhoea, 1990). There have been a number
of studies investigating prophylactic zinc supplementation and its role in diarrhoea.
A recently published Cochrane review also supports the role of zinc in treating
diarrhoea in children. In the 22 trials reviewed, zinc was seen to shorten the duration
of an episode of diarrhoea. However, there was no benefit demonstrated in children
under 6 months (Lazzerini & Ronfani, 2008). Due to the positive results of studies
on zinc supplementation in children, the WHO/UNICEF now recommend zinc
supplementation for the treatment of all episodes of childhood diarrhoea
(WHO/UNICEF, 2004). Although there is strong evidence to support the
supplementation of zinc in children, the majority of the studies on zinc
supplementation have been conducted in children in developing countries and,
therefore, may not be applicable to the adult population in developed countries.
Nonetheless, dietitians should be more aware of zinc losses that can occur as a result
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of CDAD diarrhoea. In particular, if diarrhoea is persistent, zinc supplementation
should be considered, especially if nutritional intake is inadequate.

3.5.10 Limitations and future considerations
An aspect not considered in the design of this study was dietitians’ personal
consumption of probiotic products. In previous studies, this has been reported to
influence dietitians’ professional practice.

In a study of Korean dietitians, the

dietitian’s own frequency of consumption of FF had a significantly positive effect on
their recommendation of such foods and those who ate FF demonstrated a more
positive attitude towards the efficacy of such foods. The authors of this study
expressed concern that these findings may result in some dietitians providing
misleading advice to consumers, because the advice provided was not necessarily
based on scientific knowledge (Cha et al., 2010). An additional factor not explored
as part of this study was methods dietitians use to obtain information about
probiotics.

The study of Dutch dietitians showed that they got most of their

information from journals, magazine articles or the internet, but would have
preferred if information had been provided by independent scientists instead of
through product promotions. Specific information requested was about the safety
and functionality aspects of the probiotics (de Jong et al., 2004).
An important issue to be addressed from these study results is that dietetic practice in
the use of probiotics is not underpinned by scientific research. Similar findings on
the opinions and use of probiotics have been reported among gastroenterologists in
the US. Williams et al., (2010) reported that gastroenterologists believe that there is a
role for probiotics in patient care but actual practices did not concur with the
published expert panel based recommendations for evidence based probiotic use.
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Cha et al., (2010) commented on the need for undergraduate students of nutrition and
dietetics to learn about FF from a scientific, evidence-based approach and that
education about FF should be provided as continual professional development for
practicing dietitians.
Given the vast amount of research into the efficacy of probiotics in different clinical
conditions, the need for guidance for healthcare professionals, perhaps in the form of
clinical practice guidelines should be considered.

One of the most consistent

findings in health service research is the gap between best practice as identified by
scientific research and the actual clinical care provided (Grol & Grimshaw, 2003;
Brown et al., 2004). Several studies have suggested that 10-40% of patients do not
receive care that is based on current scientific evidence and that this deficit in
evidence-based practice results in care that is either unnecessary or is potentially
harmful in ≥20% of cases (Avezum et al., 2000; Grol & Grimshaw, 2003; Leape et
al., 2003; Mc Glynn et al., 2003). A cross-sectional survey in a Swedish University
Hospital explored dietitians’, occupational therapists’, and physical therapists’
attitudes towards evidence-based practice. All professions were reported to have
positive attitudes towards evidence-based practice and support the use of evidence in
decision making about patient care. Although the groups had good knowledge about
research terminology, they lacked understanding of the specific terminology relating
to evidence-based medicine. Lack of time was given as a barrier to the use of
evidence-based care (Heiwe et al., 2011).
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3.6 Conclusion
This is the first study to describe Irish dietitians’ opinions on, and use of, probiotics,
and their current practice in the management of CDAD. The role and efficacy of
probiotics in the prevention and management of CDAD is an area of emerging
research and understanding.

We need a greater understanding of the complex

interaction between the human gastrointestinal microflora, pathogens, probiotics and
antibiotics and to increase our knowledge about the role of probiotics in CDAD. The
low cost, good safety profile and low risk of infection make probiotics a favourable
option in the prevention and treatment of CDAD, provided sufficient evidence
becomes available to support their use. Studies of appropriate statistical power and
adequate follow up are necessary to provide insight into the efficacy of particular
bacterial and yeast strains and the doses of these strains that are most likely to
prevent CDAD and its recurrence, and treat CDAD should it develop.
The findings of this study indicate that Irish dietitians have mixed views about the
role of probiotics in CDAD. Despite this, they frequently recommend probiotics in
their clinical practice either orally or via enteral feeding tubes, with little
standardisation of practice apparent. The probiotic strain recommended or available
to prevent or treat CDAD frequently does not contain the strain for which evidence
exists. Guidelines or polices in Irish healthcare facilities for probiotic use are lacking
or not consistently referred to by Irish dietitians. Guidance on the use of probiotics
in CDAD should be sought from current scientific literature and the development of
consensus practice guidelines for dietitians managing patients with CDAD is
essential.
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Although the majority of Irish dietitians use a polymeric feed when enterally feeding
patients with CDAD, practice on the provision of dietary fibre to this patient group is
variable. The provision of additional vitamin and mineral supplementation is also
dependent on the dietitian’s clinical judgement. The enteral feeding practices of Irish
dietitians in this patient group need to be compliant with scientific evidence. From
the review of the literature there are a number of considerations for dietetic practice.
Those at high risk of developing CDAD elemental and semi elemental feeds should
be avoided. A source of fibre should be provided when enterally feeding a high risk
patient. In cases of CDAD where diarrhoea occurs the provision of additional
vitamins and minerals should be considered to account for increased losses.

Irish dietitians in this study identifed themselves as the main healthcare professional
to recommend probiotics. However the survey found that there was underutilization
of current scientific evidence and guidelines to conform with evidence-based
practice. Health professionals need to remain competent in their knowledge of this
developing area of research and be able to translate research findings into their
professional practice (Schultz et al., 2011).

To achieve this, it is vital that

information on FF is correctly communicated to those involved in nutrition education
and health promotion (Blades, 2000). Given the increasingly widespread availability
and use of probiotics in both community and hospital healthcare settings, Irish
dietitians need to acquire a thorough understanding of these products, including the
risks and benefits of probiotic treatment and the effectiveness of probiotics using
different modes of delivery.

If probiotics are recommended to prevent or treat

disease in patients, consideration must be given to quality control and documentation
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of the efficacy of such treatment.

It is imperative that dietitians develop their

knowledge about probiotics so that they are able to convey science based information
to their clients and healthcare professionals and their credibility as nutrition experts
is strengthened (Hetherwick et al., 2006).
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4.1 Conclusions and Recommendations

This study looked at a number of aspects involved in the dietetic management in
patients with CDAD in Ireland. The first study’s aim was to assess the nutritional
status of patients with CDAD and compare this to a group of hospital patients. The
study found there was no significant difference in MUST scores between a group of
patients with CDAD and a comparative hospital patient group. However the CDAD
group did have a significantly lower BMI and were a significantly older. In addition,
when the data from the CDAD group were compared to malnutrition data from other
Irish studies, there was a higher prevalence of malnutrition (as determined by BMI)
and of malnutrition risk (as determined by MUST) in the CDAD group in this study.
These findings would indicate that hospitalised patients with CDAD are at high risk
of malnutrition.
The second study investigated dietitians’ opinions and uses of probiotics in CDAD
and other clinical conditions. It also looked at the enteral feeds being provided to
these patients should tube feeding be required. This study showed that Irish dietitians
have inconsistent views on the role and use of probiotics in different clinical
conditions. What has emerged from the work is that probiotics are being
recommended by dietitians in clinical conditions for which insufficient evidence
exists, in particular patients with CDAD. It is also clear that a variety of probiotic
products are being supplied within Irish health care facilities, that knowledge of the
specific benefits and limitations for particular strains is poor and that very little
guidance for their use exists. The study also showed that general enteral feeding
practices varies among dietitians, specifically in the provision of feeds containing
dietary fibre.
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From the findings of this study and reviewing the literature a number of conclusions
and recommendations are made:


The dietetic profession should continue to support and be involved in the
promotion, training and implementation of nutritional screening for all patient
groups in both the hospital and community setting.



Dietitians should be aware of the risk factors for the development of CDAD;
in those patients at high risk who require enteral feeding the provision of
feeds containing dietary fibre and the avoidance of elemental and semi
elemental feeds should be considered. Supplementation of micronutrient
intake including zinc in patients who develop CDAD may be beneficial.
Medical and nursing staff should be aware that patients with CDAD are a
patient group at high risk of malnutrition and instigate care plans that address
this risk.



Probiotics should not be recommended for use in either the prevention or
treatment of CDAD, until there are further supportive trials in the area. The
author is unwilling to make a recommendation endorsing any product for any
patient group for the treatment or prevention of CDAD as this would
contravene current evidence. The probiotic S. bouldarii for which there is
some limited evidence is not available in Ireland. However, in countries
where this product is available international guidelines do not recommend it
use due to safety concerns.



There is a need for education for practicing dietitians on the role of probiotics
in clinical practice.

This education should be continuous to capture the

emerging evidence in the area.
127

The information provided should be

independent of commercial influence and provide a balanced view of the
scientific evidence.
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Appendix 1 – The Mini Nutritional Assessment form
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Appendix 2 – The Malnutrition Universal Screening Tool and supporting documents
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Appendix 3 – Consent form for patients with Clostridium difficile associated disease

PARTICIPANT INFORMATION AND CONSENT FORM
STUDY TITLE:
Nutritional status of patients with Clostridium difficile-associated Diarrhoea (CDAD)
This is part of a larger study that is examining:
Immune Response and Molecular Epidemiology of Clostridium difficile-associated
Diarrhoea (CDAD): A Prospective Study.
The principle investigator is: Dr Lorraine Kyne
Researcher: Yvonne Hickey
You are being invited to participate in a research study. Thank you for taking time to read
this.
WHAT IS THE PURPOSE OF THIS STUDY?
Clostridium difficile is a bacterium, which causes diarrhoea in some patients who have
taken antibiotics. Different strains of C. difficile diarrhoea have been responsible for
major outbreaks of diarrhoeal illnesses in the UK and Canada. As part of this study we
want to look at the nutritional status of patients diagnosed with C. difficile diarrhoea.
Also to examine how C. difficile diarrhoea affects nutritional status of patients over a
defined time period.
WHY HAVE I BEEN CHOSEN?
You have been invited to participate in this study because you are suffering from diarrhoea,
caused by the C. difficile bacterium. We will be asking all patients with C. difficile diarrhoea
to consider participation in the study. We hope to enrol approximately 150 patients over
the next 18 months
WHAT WILL HAPPEN IF I VOLUNTEER?
Your participation is entirely voluntary. If you initially decide to take part you can
subsequently change your mind without difficulty. This will not affect your future
treatment in any way. Furthermore your doctor may decide to withdraw you from this
study if he or she feels it is in your best interest. If you agree to participate, you will be
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requested to complete an interview. We will record information from your medical records
on treatment, tests and general health. In addition, information will be gathered regarding
your recent weight history and dietary intake. We will also take measurement of you
weight, height, tricep skinfold thickness, upper arm and calf circumference and hand grip
strength. While you are in the hospital a researcher will contact you to re assess your
dietary intake and nutritional status, and will repeat the measurements that were initially
taken.
ARE THERE ANY BENEFITS FROM MY PARTICIPATION?
By participating in this study you will help researchers identify the nutritional status of
patient who develop C. difficile diarrhoea and how it is affected after people develop C.
difficile diarrhoea .
ARE THERE ANY RISKS INVOLVED IN PARTICIPATING?
We do not anticipate any discomfort or potential risks associated with participation in this
study.
WHAT HAPPENS IF I DO NOT AGREE TO PARTICIPATE?
If you decide not to participate in this study your treatment will not be affected in any way.
CONFIDENTIALITY
Your identity will remain confidential. A study number will identify you. Your name will
not be published or disclosed to anyone.
COMPENSATION
The researchers are adequately insured by virtue of their participation in the clinical
indemnity scheme.
IS THIS STUDY SAFE AND BENEFICIAL?
The St. Vincent’s Healthcare Group, Ethics and Medical Research Committee have reviewed
and approved this study.
WHO IS ORGANISING AND FUNDING THIS RESEARCH?
The main study is funded by a grant from the Health Research Board and is organised by Dr
Lorraine Kyne, Consultant Geriatrician, Mater Hospital.
Research Team CONTACT PHONE: 01 716 6345
Principal investigator: Dr. Lorraine Kyne, Phone: 01 803 4242 or 01 716 6301
Consultant Physician in Medicine for the Older Person, Medicine for the Older Person Day
Ward, Mater Misercordiae University Hospital.
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Researcher:
Yvonne Hickey, Dietitian, St Vincent’s University Hospital
Dr. Lynda Fenelon, Consultant Microbiologist, St Vincent’s University

PLEASE TICK YOUR RESPONSE IN THE APPROPRIATE BOX
I have read and understood the Participant
YES  NO 

Information

I have had the opportunity to ask questions and discuss
the study

YES  NO 

I have received satisfactory answers to all my questions

YES  NO 

I have received enough information about this study

YES  NO 

I understand that I am free to withdraw from the study
at any time without giving a reason and without this
affecting my future medical care

YES  NO 

I agree to take part in the study

YES  NO 

Participant’s Signature:

Date: _________

____________________________

Participant’s Name in print: __________________________
Witness Signature:

_______________________________

Witness Name in print:

____________________________
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Date: _________

Investigator’s Signature:

___________________________ Date: _________

Investigator’s Name in print:

________________________
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Appendix 4 – Data collection record for patients with CDAD
Study ID_______

Date:___________

Name: Initials
Location / Ward
Sex: Male  Female

Race :

MRN
Date of Birth / age
Date of C Diff positiv
Admission date
Admitte from:

Home  Nursing Home  Rehab Hospital 
Other ____________________

Previous sta on his
admission in:

ICU 

HDU 

Hospitalised in previous 30
days

yes

no 

Dietetic intervention

Yes

no
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Weight
Method
Odema present

Yes  No
Mild moderate severe
Yes  No
Mild moderate severe 

Usual weight

Reported weight

% Weight loss

Weighthistory

Height
Reported

stadiometer

Ulna length

Ulna length

Mid upper arm circumference
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Nutritional Intake
Oral intake in past five days

Normal



Less than normal 
Very little / none 
Diet Consistency
Fluid Consistency
Coeliac Disease

yes 

no 

Oral Nutritional Supplements
Yes  No 

Enteral feeding

NG NJ PEG RIG
Date PEG/RIG inserted _______________

Date feeding Commenced
Feed type
Feed Rate
TPN

Regimen details

Total volume
Date Commenced
Probiotic charted on drug kardex

Previous probiotic se
Vitamin and mineral supplement
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Appendix 5- Data collection sheet for Control group

Patient
Number

Age

Yrs
1
2
3
4
5
6
7
8

Sex

M/F

Type
of
ward*

1-5,*8

Diagnostic
Category**

1-7**

Oedema
Present?

Has MUST
been
completed?

Y/N

Y/N - if no,
complete
tool. If yes give score,
e.g Y-2.

If MUST
was done,
is their
evidence of
an
appropriate
care plan?

Step 1Score

Height (m) - if not available,
calculate from Ulna Length
Weight (Kg)

BMI
Kg/m2

Actual
Y/N

Recalled

N/A***

Actual

Recalled

Calculated

Patient Number

1

Unintentional weight loss (past
3-6 months)

Kg

Step 2-Score

Likely
food
intake
over
next 5
days

Food
intake
over past
5 days

Less than
normal

Normal

2
3
4
5
6
7
8
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V. little or
none

Normal

Step 3 Score

Less than
normal

V.
little
or
none

MUST
Score

;;;n ~ »

8g !tl "'C

~!ii

App~

to all pat ients , residents and dients irnspe ctive of thei'

perceived infection ri sk

Whe n the patie nt has had at lea st 48 hours withovt diarrhoea and has
had a form ed/normal stool for that patient. Contact Precautions can
b e dis continue d , HOWEVER STANDARD PRECAUTIONS MUST BE
CONTINUED

PATIENT PLACEMENT

Indude the potential for transmission of infectious agents in patient
placement decisions.
'M1ere possble, place patients.....ho contam nate the environment
or (Klnot mantain appropriate hygiene in sng le rooms,

Place all patients with suspected or known CDAD in a single room with
cl inical hand wasting sink and ensloite facili ties. If ensuite facilitie s are not
available. dedicate toilet or commode for patients' sole use.
Place a notice on t he isolation room door advising those entering t o report to
staff-in-charge before entering.
In an outbreak situation, if the numbel" of patients with CDAD exceeds the
availability of single rooms, alternative placement options include:
Cohort ward or bay with a dedicated nursing staff for t he area.
Isolation / dedicated ward in the event of a large outbreak.

180

PATIENT MOVEMENT
AND TRANSFER

Limit the moveme nt and transport o f the patient to essentia l purposes
only,
Priorto patient transfer

Q "'C

Remove contaminated aprons/gowns and gloves and dispose and perform
hand hygiene prior to transporting patients.
Don apron/gown and glCNes prior to handling the patient at the transport
destination .
Prior to acceptng a patient with CDAD, it is the responsibility of the
receiving facility to ensure compl iance with single room, clinical hand
washing sir*, ensuite facilities and Contact Precautions. The receiving ward/
department, bed manager must be notified .
Transport equipment (stretdler, bed, wheeldlair) used for the transfer must
be cleaned and disinfected before use with another patient/resident.
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Appendix 6 – the Health Protection Surveillance Centres infection guidelines for patients
with Clostridium difficile associated disease (HPSC, 2008).
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HAND H YGIENE

Patients should wash
their hands after
t oi!eting and before
meals. Hew should
provide assistance
with hand washing for

those patients who are
unable to perform hand
washing independently

Hand Hygie ne is recommended:
a

~and

.a..fulr. each episode of patie nt contact

• Betvveen individual patient contacts.

Aftm: cont act with b lood, body fluids . secretions or excretions,
whether or not gloves are worn.

Aft.m handling soiled/contaminated equipment, materials or the
environment.

Immediately after removing gloves or o t her protective clothing
Hand may be decontaminated using both plain soap and warm
water o r if h ands are physically dean, an alcoh ol based hand ru b.

GLOVES

193

Should be worn as
single u se item s
Should conform to
European Community
Stan dard s.

In addition to carry ing out ha nd hygiene as required in Standa rd
Precautions

Gloves are recommen d ed:
For all act;...ities that carry a risk of exp osure to blood, body fluids,
secretions o r excre tions, sharp s orcontaminated instruments
When touching mu cous membranes and n on-intac t skin.
When handling contaminated equipment, e.g. commodes o r
bedpans.

Hand s should be washed before and after each contact with patient
equ ipment
Hands should be washed with soap (anti microbial or non-a ntimicrobial) and
water.I'll
None of the age nts (including alco hols, chlorhexidine, iodophor'S or
triclosan) used in a nt iseptic ha nd-w as h o r a nt iseptic hand-rub preparations
are reliably sporicidal against C. difficile. Th e physical action of ru bbi ng
and rinsing is the only way to re m ove spores from hands .

In addition t o wearing g loves as required for Standard Precautions, wear
gloves wh en entering a room for all interactions that may invowe contact with
the patient or potentially contaminated areas in the patients environment.

~
~

"

Remove gloves
Immediately afte r contact w ith any infective material
Before touching non-contaminated items a nd environmental surfaces

Gloves should be:
Put on immediately before an episode of patient con tact, and
removed as soon as the activity is completed
Changed between caring for different patients and between
different care activities on the same patient.
Disposed of as health care ris k was te if contaminated with blood,
body fluids

S<

EYE , NASAL AND
MOUTH PROTECTION
(e.g., goggles, visors
and face masks)

Facemasks and eye pro tection are recommended where there is a
risk of b lood, body fluid s, secret ions or excretions sp las hing into th e
face or eyes.
Masks should be single use a nd fl u id resistant.

Before leaving the patients environmen t
Wash hands as above immediately after glove removal.

§
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~
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•
APRONS

Disposable plastic aprons should b ewom where there is a risk.
that clothing or skin may become exposed to blood, body fluids,
excret ions or s ecretions.
Fluid repellent gowns may be required if there is a risk of extensive
eJq)osure to the above.

In addition to w earing apron/gowns as required (or Standard Precautions,
wear aprons/gowns when entering a roo m for all interactions that may
involve contact with the patient or potentially contaminated areas in the
patient s' e nvironm en t.

Remove apron/gown
Immediately after contac t with any inf ective material
Before leaving the patients environment

Wash hands as above immediately after apron / gOlNn removal.
PATIENT CA.RE

EQUIPM ENT

Handle equipment soiled wit h b lood, body fluid s. secretions and
excret ions in a man ner that preve nts skin and mucous membranes,
cont amination of clothing, and tran sfer of micro-organisms to other
patients and environments.
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Ensure that reusable equipment is not used by another patie nt
until it has been cleaned and rep rocessed appropriately.

Dedicate medical devices (e.g., thermome ters, s phyg mo man ome ters,
stethoscopes, glucose metres) to single patient use and d isposa b le
materials used wh e never possible.
On ly take essential eq uipment and supplies into the roo m . Do not
stockpile as unused s tock will have to be discarded on cessation of
Isolation Contac t Precaut ions.
Patient charts/records should not be tak e n into the room.
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~

LAUNDRY CARE:

Laundry shou ld be h andled and transported in a manner that
prevents transmission of micro-organisms to othe r patie nts,

In add ition to hand ling a nd tra ns porta t ion of laundry as required for
Standa rd P reca utions:

HeWs or the environm ent.

Laundry shou ld be categorised and segregated according t o
recommended guidel in es
Staff handling soiled linen s h ould wear gloves and a disposable
plastic apron.

Soiled and infectious linen should be carefully placed in an
a lg inate s titc hed o r water sol u ble bag wi th a tie. Then place
bag into a colour-c:oded l aundry bag which should be secu rely
closed prior to transport to an approved laundry capable o f

dealing with potentially contaminated linen
Staff shou ld not manually sluice or soak so~ed or infected linen
Idatning because o f the risk of c ross in fecti on ~26
Soiled linen should be tra nsported and stored safely.
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Linen should be h eat disinfected during th e wash p rocess by
raising the temperature to e ither 6S"C for not less then 1 0
minutes o r preferably 71 "C for not less then 3 minutes.
Disinfection o f heat labile materials (according to manufacturer
instructions) can be achieved at low temp eratures by
150 ppm of chlorine into t he penultimate rinse.
DECON TAMINATION
OF MEDI CA L DEVIC ES

All laundry s hould be carefully pl aced in an alginate stitched o r water soluble
bag and then placed into a laundry bag clearly identified with label s, co lourcoding or o t he r m ethods prior to transp o rt to an approved laundry capab le
of dealing wit h contaminated line n .
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Medical d evices designated as "Singl e Use Only" must not be
re processed or reused under any circumstances (MDA DB 2000),
(M[x) 93/42/EEC

2
This symbol means "Single Use Only " (BS EN 980:1997).
Reusable medical devices should be cleaned and reprocessed
accordi ng to the manufacturer's in structions and local po li cy.

~
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MANAG EMENT OF
HEALTH CARE RI SK

WASTE :

Dispose of healthcare risk waste in accordance wi t h the
Department of Health & Children's National Guidelines for Waste
Disposal,:m whic h outlines the categorisation and segregation of
health care waste.

Waste contaminated with diarrh oea from a suspected or known CDAD
patient snould be disposed as healthcare risk waste with in a healthcare
faci lity
No additional precautions are needed for non-healthcare waste that is being
removed from rooms of patients on Contact Precautions

DISPOSAL OF SHARPS:
Syringes and needles sh ould be disposed o f as a single unit.
Used sharps shou ld be carefully discarded into designated
sharps cont ainers at, the poin t o f use.
Need les should not be re-capped, bent , broke n or
disassembled .
Sharps shou ld no t be passed from person to person by hand.
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Guidel ines should be availab le at local IeYe I on the management
of needle stick a nd sharps injuries.
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SPILLA G ES

Spillages of blood, urine, faeces or vomit s hould be dealt with
immediately wea ring prot ective clo t hing (i.e. disposa b le gloves
and apron).

Fo r spilla g es o f b ody fluid (e.g ., urine, faeces o r vomit),
Soakup as much afthe visible mate rial as possible with disposab le
pape r towels.
Dispose of the soiled paper towels according to natio nal
guidelin es.
Clean the area usi ng warm wa t er and general purp ose neutral
detergent.
Disinfect using a chlori ne-releas i ng solution o f 1000ppm, o r
equivalent according to manufacturers' instructions, rinse and
d",_
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Wash and dry han ds thoroughly.

I

Do not a p ply c h lorine-based disinfec tants direct ly onto spillages
of urine as it may result in t he release of ch lorine vapou r.

5

Discard gloves and apron according to n a ti onal guidelines.

Fo r b lood s p ill ages:
Decontaminate a ll blood spills wit h a c hlorine based disi nfectant
(e.g .. powder. g ran ules o r liq uid con taining 10.000ppm available
chlorine) or suitab le al t erna tive. in li n e with t he man u fac tu rer's
instructions and local pol icy.

l
~

~

Wipe up the spillage wit h disposable paper towels a n d disca rd
into a yellow plastic bag . Wash the a rea wit h a general purpose
neu tral d etergent and water.
Discard gloves and apron according to national g u ideli nes.
Was h a nd dry hands tho roughly
For a ll suriaces/items cont aminated with blood or body fluids.
following deani n g d isinfect using a chlorine-releasing solution of
1COOppm . o r equivalen t according to manufacturers instru ctions.
rinse and dry.

~

Appendix 7 – St Vincent’s University Hospital Infection Control guidelines for Clostridium
difficile associated disease.

SI Vincent 's Heallhca re Grou p
10.

INFECTIOUS DISEASES

10.1. Ove n ' jew of Infectio n C ontrol Ma nagement of Infectious Dis eases
The infec tion preve ntion and control (lPe) team should be in formed promptly if any patient
known or suspected to have any of the following in fections is admitted (ext 4948/4088. bleep 122).
Duration o f isolation varies accordi ng to the infection with w hich the patient had been diagnosed.
Some infections require tha t the patient be iso la ted for the entirely of their hospital stay ; wi th other
infections. the patient m ay be removed from isolatio n o nce t hey have been sy mptom-free for a

specified time period, or have had appropriate treatment for a spec ified time. Further information
o n some infec tio ns may be found furthe r on in this section; otherwise. p)easc d iscuss w ith the IPC
team.
Recomme ndatjons may be subject to c hange following assessment by the IPC team

For thc llI:1uagcmcnl or pallcnls In Isolalloll , plcase re rcr 10 Guld cllncs on numagc mcnt or
paticnts in Isolation (Section 30).
Notm"blc

InrccUvc nl<.ltcrl411

Dl sc~,sc

AddilIOll<.11
Precautions

Isolutlon rC(lulrcd

Campylobacter

Yo<

Faeces

Contact

Single room

Chickenpox
(Varicella zoster
virus)

No

Respiratory secretions
Lesion secretions

Airborne
Contact

Single room

Chole ra

Yo<

Faeces

Contact

Not required

Clostridium
dijficUe

No

Contact

Single room

CreutzfeldtJakob disease

Yo<

Faeces
Faccally contaminated
objects and surfaces
Brdin . spinal, cranial and
dura mater
Optic nerve and retina

(CJD)

Seek advice from
Infection control

Not required

Varian! CJD
(vCJ D)

Yo<

As above and lymphoid
tissue

Diphtheria

Yes

Oral & nasal discharges

Droplet

Single room

Ecoli0 157

Yo<

Faeces

Contact

Single room

Haemophilll.!'
illj114e'lzae B
{invasive)

Ye,

Respiratory secretions

Droplet

Not required
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St Vincent's Hea lthcare Group
10.5. ClostridiulII di/Jicile
This is a NOTIFIABLE DISEASE
AGENT:

ClostridiulIl cliffici/e

INCUBA T ION PERIOD:

Variable

TRANSMISS ION:

Environmental contamination
Hands of hcalthcarc workers
Faeca l-oral.

PREDISPOSING
FACTORS:

Antibiotic therapy. especially ccphlusporins, clindamycin and
quinolones (e.g., ciprofloxucin)
Exposure to infected patients

INFECTI VE
MATERIAL:

Faeces
FaecaUy contaminated o bjects/surfaces

DURATION OF
INFECTIVITY:

While symptomatic, and until free o f symptoms for 72 hours

PRECAUTIONS:

CONTA CT PRECAUTIONS
Isolation of the patient in a single room until free of symptoms
for 72 hours.
In the event of non-availability of a single room, cohorting of
patients with C. difficile may have to be considered
A commode should be secured for the sole use of the infected
patient.
Environmental cleaning with I,OOOppm hypochlorite.

T REATMENT:

Discontinue anljbiotic therapy if c1jni cally feasible.

Do not use anti-diarrhoeal agents
Metronidazole ill vancomycin orally, depending on clinical
severity

PERI OD OF
ISOLATION:

From onset of symptoms, until symptom free for 72 hours
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Appendix 8 – Cover letter and survey to members of the INDI
School of Biological Sciences,
Kevin Street,
Dublin 8
9th of March 2010
Questionnaire - Dietetic practice in Ireland - The use of probiotics and enteral feeding in
patients with Clostridium difficile associated diarrhoea
Dear Member
I am a dietitian working in St Vincent’s University Hospital and am currently completing a
Masters degree with the School of Biological Sciences, Dublin Institute of Technology under
the supervision of Dr. Clare Corish.
My primary area of research is an investigation of the nutritional status of patients who
develop Clostridium difficile infection in hospital. However, in recent years, a number of
studies have been published on the use of probiotics as an emerging therapy in both the
prevention of Clostridium difficile (Hickson et al. 2007) and the treatment of patients who
develop this infection (Mc Farland, 2006). I now wish to investigate the current use of
probiotics in dietetic practice focusing on patients with Clostridium difficile. In addition I
would also like to ascertain Dietitians’/ INDI members’ opinions regarding the use of
probiotics in the management of Clostridium difficile and other medical conditions.
To obtain this information, I am circulating this questionnaire to all members of the INDI.
The questionnaire will collect some demographic data on respondents (e.g. place and area
of work, years practicing), and information on the use and administration of probiotics in
patients with Clostridium difficile associated diarrhoea. The questionnaire will also include
questions relating to the dietetic management of enterally fed patients who develop
Clostridium difficile associated diarrhoea.
The questionnaire is divided into 4 sections and will take approximately 5 minutes to
complete. Please complete each section providing me with your opinions and current
practices and return in the included stamped addressed envelope by the 31 st of March
2010.
All completed questionnaires will be entered into a draw to win a € 75 One 4all gift
voucher in appreciation of your help and time with this
If you have any queries, please do not hesitate to contact me.
___________________________________
Yvonne Hickey y.hickey@st-vincents.ie
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Section 1 - Baseline Details
(a) Gender
Male

Female

(b) Place of employment
Hospital

please name hospital: ____________________________

Community dietetics

please name HSE area: _____________________________

Private practice
Student
Other

please state:_____________________________________

(c) How many whole time equivalent (WTE) dietitians work in your department?
_________________________________________
(d) How many years have you been working as a qualified dietitian?
Less than one year

1-5 years

6-15 years

16-25 years

+ 25 years

(e) Which best describes the patients you work with?
Paediatrics
Adults
(f)What areas of dietetic practice do you currently work in ( e.g. care of the elderly , surgery,
gastroenterology, etc……)

___________________________________________________________________________
Section 2 – Your Opinions
(a)Do you think probiotics have a place in dietetic practice in the prevention of
Clostridium difficile?
Yes

No

Don’t know

Please give a reason for your
answer:____________________________________________________________________
________________________________________________________________________

202

(b) Do you think probiotics have a place in dietetic practice in the treatment of
Clostridium difficile?
Yes

No

Don’t know

Please give a reason for your
answer:____________________________________________________________________
___________________________________________________________________________
(c) Would you recommend the use of probiotics in your clinical practice in any of the
following clinical conditions?
I do not recommend the use of probiotics
OR
Liver disease
Inflammatory bowel disease
Irritable bowel syndrome
Small bowel bacterial overgrowth
Acute gastroenteritis
Necrotising enterocolitis
Other conditions:
__________________________________________________________________
___________________________________________________________________

Section 3 - Probiotics in practice
(a)Does your hospital/place of work have a policy/guidelines for the use of probiotics?

Yes

No

(b) Does your hospital/place of work have a policy/guidelines for the use of
probiotics specifically in patients with Clostridium difficile associated
diarrhoea?
Yes

No

(c) Does your hospital/place of work use/supply probiotics to patients?
Yes

No
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(d) Do you use probiotics in the prevention of Clostridium difficile associated
diarrhoea in at risk patients ?
Yes
No
Occasionally
(e) Do you use probiotics used in the treatment of Clostridium difficile associated
diarrhoea?
Yes

No

Occasionally

(f) If probiotics are commenced in patients with Clostridium difficile associated diarrhoea,
who generally recommends their commencement? (Choose more than one option if
appropriate)
Not applicable

Microbiologist

Dietitian/clinical nutritionist

Nursing Staff

Medical staff

Pharmacist

Other ____________________
(g) If probiotics are commenced, who recommends their commencement most often?
(Please classify 1-4, 1 being the most often, 4 not as often)
Not applicable
1. ____________________2.____________________
3.____________________ 4.____________________
(h) In what form are the probiotics given?
Yogurts containing probiotics

Tablet / Capsule

Yogurt drinks containing probiotics
(i) What different brand(s) of products are used (please specify product and type eg
yogurt and brand
___________________________________________________________________________
___________________________________________________________________________
(j) If probiotics are used, what strain(s) of probiotic is used?
Unknown
Strain(s):___________________________________________________________________
___________________________________________________________________________
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(k) If probiotics are used, what determines the strain of probiotic or brand of products
used in patients with Clostridium difficile associated diarrhoea? (More than one option
can be chosen)
The clinical evidence
The product supplied by catering
The product supplied by pharmacy
Hospital guidelines
Medical/ Microbiological opinions
Other:_____________________________________
(l) Do you recommend administration of probiotics to patients who develop diarrhoea? If
the diarrhoea is not caused by Clostridium difficile and who are on antibiotics?
Yes

No

Occasionally

(m) Do you recommend administration of probiotics to patients who develop diarrhoea?
If the diarrhoea is not caused by Clostridium difficile and is of unknown origin?
Yes

No

Occasionally

(n) Would you recommend the commencement of a multivitamin or mineral supplement
in a patient who is Clostridium difficile positive? (more than one option can be chosen)
Yes, always

Would depend on patient’s diagnosis

Would depend on patient’s nutritional status
Other reason: ________________________________________ _____________________

Section 4– Enteral feeding
(a) Do you recommend administration of probiotics via enteral tubes if a patient being
tube fed gets Clostridium difficile associated diarrhoea?
Yes

No

Occasionally

Not applicable

(b) Do you recommend administration of probiotics via enteral tubes to patients with
other clinical conditions ?
Yes

No

Occasionally
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Not applicable

(c)If a tube fed patient develops Clostridium difficile what type of feed would you use
most often?
Fibre containing

Semi elemental

Non fibre containing

Elemental

A mixture of fibre and non fibre containing

Feeding is withheld

Parenteral nutrition is commenced
Please provide any further comments you may have on the use of probiotics and/or
nutritional management in patients with Clostridium difficile associated diarrhoea?
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
_______________________________________________________________
Thank you for taking the time to complete this questionnaire.
Your response and time is greatly appreciated.
Please return in included envelope
Yvonne Hickey ,Dietitian
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Appendix 9 – Irish Hospitals represented by responses from dietitians.
Hospital

Adelaide and Meath Hospital Incorporating The National Childrens
Hospital
Beaumont Hospital
Bons Secours Cork
Bons Secours Dublin
Cavan General Hospital
Connolly Hospital Blanchardstown
Cork University Hospital
Kerry General Hospital
Letterkenny General Hospital
Mary’s Hospital Phoneix Park
Mater Misericordiae University Hospital
Mater Private Hospital
Mayo General Hospital
Mercy Univeristy Hospital Cork
Merlin Park University Hospital Galway
Mid Western Regional Hospital Dooradoyle
Midland Regional Hospital Mullingar
Midland Regional Hospital Portlaoise
Midland Regional Hospital Tullamore
Monaghan General Hospital
Mount Carmel Hospital
Mount Carmel Hospital
Naas General Hospital
Our Lady’s of Lourdes Hospital Drogheda
Our Ladys Children Hospital Crumlin
Portiuncula Hospital
Roscommon County Hospital
Sligo General Hospital
South Infirmary Victoria Univeristy Hospital Cork
South Tipperary General Hospital
St Columcille’s Hospital
St Finbarrs Hospital, Cork
St James Hospital
St Lukes Hospital Rathgar
St Lukes Kilkenny
St Michaels Hospital Dun Laoghaire
St Vincent’s Private Hospital
St Vincent’s University Hospital
Temple Street Childrens Univeristy Hospital
The National Maternity Hospital
University Hospital Galway
UPMC Beacon Hospital
Waterford Regional Hospital
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Appendix 10 - Probiotic products supplied in hospitals

Product
Probiotic
name and
Genus , species, strain(commercial
manufacturer strain designation) in the product
Everybody
Lactobacillus rhamnosus GG
Yoplait
Actimel
Lactobacillus bulgaricus
Danone
Streptococcus thermophilus
Lactobacillus caesi Imunittas ( DN114001)
Yakult
Lactobacillus caesi Shirota
Yakult
Udos Super 8 Lactobacillus acidophilus
Lactobacillus rhamnosus
Streptococcus thermophilius
Lactobacillus plantarum
Bifidobactermium bifidum
Bifidobacterium longum
Lactobacillus bulgaricus
Lactobacillus salivarius

Form

Yogurt drink
Yogurt drink
Yogurt drink
Capsules

Acidophilus
Complete
Sona

Lactobacillus Lactis
Lactobacillus Acidophilus
Lactobacillus Para Casei

Capsules

VSL # 3
Living Shield

Streptococcus thermophilus
Bifibobacterium breve
Bifibobacterium longum
Bifibobacterium infantis
Lactobacillus acidophilus
Lactobacillus plantus
Lactobacillus paracasei
Lactobacillus bulgaricus

Sachet
To be added to water

Old Mac
Donnells
Farm Natural
Yoghurt
Old Mac
Donnells
Farm
Activa
Danone

Lactobacillus bulgaricus, Streptococcus
thermophillus, Bifidobacterium longum ,
Lactobacillus acidophilus

Yogurt

Lactobacillus bulgaricus
Streptococcus thermophilus
Bifidobacterium Acti Regularis
Bifidobacterium BB12 r

Yogurt

Mixed seeds
yogurt
Yoplait
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Yogurt

Product
Probiotic
name and
Genus , species, strain(commercial
manufacturer strain designation) in the product
Yogurt
Adults products
Glenisk
Active cultures –Streptococcus thermophilus,
Lactobacillus bulgaricus
Probiotic cultures – Lactobacillus casei,
Bifidus
Childrens products
Lactobacillus casei
Restore
Lactobacilus casei
Protexin
Lactobacillus rhamnosus
Streptococcus thermophilus
Bifibobacterium breve
Lactobacillus acidophilus
Bifidobacterium infantis
Lactobacillus bulgaricus
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Form
Yogurt

Sachet added to fluid
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